Motif 701 (n=48)
Position-wise Probabilities
Download
uniprot | genes | site | source | protein | function |
---|---|---|---|---|---|
O00444 | PLK4 | S22 | psp | Serine/threonine-protein kinase PLK4 (EC 2.7.11.21) (Polo-like kinase 4) (PLK-4) (Serine/threonine-protein kinase 18) (Serine/threonine-protein kinase Sak) | Serine/threonine-protein kinase that plays a central role in centriole duplication. Able to trigger procentriole formation on the surface of the parental centriole cylinder, leading to the recruitment of centriole biogenesis proteins such as SASS6, CPAP, CCP110, CEP135 and gamma-tubulin. When overexpressed, it is able to induce centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole during S phase. Phosphorylates 'Ser-151' of FBXW5 during the G1/S transition, leading to inhibit FBXW5 ability to ubiquitinate SASS6. Its central role in centriole replication suggests a possible role in tumorigenesis, centrosome aberrations being frequently observed in tumors. Also involved in deuterosome-mediated centriole amplification in multiciliated that can generate more than 100 centrioles. Also involved in trophoblast differentiation by phosphorylating HAND1, leading to disrupt the interaction between HAND1 and MDFIC and activate HAND1. Phosphorylates CDC25C and CHEK2. Required for the recruitment of STIL to the centriole and for STIL-mediated centriole amplification (PubMed:22020124). Phosphorylates CEP131 at 'Ser-78' and PCM1 at 'Ser-372' which is essential for proper organization and integrity of centriolar satellites (PubMed:30804208). {ECO:0000269|PubMed:16244668, ECO:0000269|PubMed:16326102, ECO:0000269|PubMed:17681131, ECO:0000269|PubMed:18239451, ECO:0000269|PubMed:19164942, ECO:0000269|PubMed:21725316, ECO:0000269|PubMed:22020124, ECO:0000269|PubMed:27796307, ECO:0000269|PubMed:30804208}. |
P02042 | HBD | S73 | ochoa | Hemoglobin subunit delta (Delta-globin) (Hemoglobin delta chain) | Involved in oxygen transport from the lung to the various peripheral tissues. |
P04049 | RAF1 | S359 | psp | RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) (cRaf) (Raf-1) | Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. {ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233, ECO:0000269|PubMed:9360956}. |
P06213 | INSR | S1033 | psp | Insulin receptor (IR) (EC 2.7.10.1) (CD antigen CD220) [Cleaved into: Insulin receptor subunit alpha; Insulin receptor subunit beta] | Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity). {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. |
P08069 | IGF1R | S1009 | ochoa | Insulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor) (IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain] | Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.; FUNCTION: When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. |
P13861 | PRKAR2A | S205 | ochoa | cAMP-dependent protein kinase type II-alpha regulatory subunit | Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase. |
P15056 | BRAF | S467 | psp | Serine/threonine-protein kinase B-raf (EC 2.7.11.1) (Proto-oncogene B-Raf) (p94) (v-Raf murine sarcoma viral oncogene homolog B1) | Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789, ECO:0000305}. |
P17612 | PRKACA | S54 | ochoa | cAMP-dependent protein kinase catalytic subunit alpha (PKA C-alpha) (EC 2.7.11.11) | Phosphorylates a large number of substrates in the cytoplasm and the nucleus (PubMed:15642694, PubMed:15905176, PubMed:16387847, PubMed:17333334, PubMed:17565987, PubMed:17693412, PubMed:18836454, PubMed:19949837, PubMed:20356841, PubMed:21085490, PubMed:21514275, PubMed:21812984, PubMed:31112131). Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA, SOX9 and VASP (PubMed:15642694, PubMed:15905176, PubMed:16387847, PubMed:17333334, PubMed:17565987, PubMed:17693412, PubMed:18836454, PubMed:19949837, PubMed:20356841, PubMed:21085490, PubMed:21514275, PubMed:21812984). Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis (PubMed:21423175). RORA is activated by phosphorylation (PubMed:21514275). Required for glucose-mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha-difluoromethylornithine in breast cancer cells when activated (PubMed:17333334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+) (PubMed:17693412). PSMC5/RPT6 activation by phosphorylation stimulates proteasome (PubMed:17565987). Negatively regulates tight junctions (TJs) in ovarian cancer cells via CLDN3 phosphorylation (PubMed:15905176). NFKB1 phosphorylation promotes NF-kappa-B p50-p50 DNA binding (PubMed:15642694). Required for phosphorylation of GLI transcription factors which inhibits them and prevents transcriptional activation of Hedgehog signaling pathway target genes (By similarity). GLI transcription factor phosphorylation is inhibited by interaction of PRKACA with SMO which sequesters PRKACA at the cell membrane (By similarity). Involved in embryonic development by down-regulating the Hedgehog (Hh) signaling pathway that determines embryo pattern formation and morphogenesis most probably through the regulation of OFD1 in ciliogenesis (PubMed:33934390). Prevents meiosis resumption in prophase-arrested oocytes via CDC25B inactivation by phosphorylation (By similarity). May also regulate rapid eye movement (REM) sleep in the pedunculopontine tegmental (PPT) (By similarity). Phosphorylates APOBEC3G and AICDA (PubMed:16387847, PubMed:18836454). Phosphorylates HSF1; this phosphorylation promotes HSF1 nuclear localization and transcriptional activity upon heat shock (PubMed:21085490). Acts as a negative regulator of mTORC1 by mediating phosphorylation of RPTOR (PubMed:31112131). {ECO:0000250|UniProtKB:P05132, ECO:0000250|UniProtKB:P27791, ECO:0000269|PubMed:15642694, ECO:0000269|PubMed:15905176, ECO:0000269|PubMed:16387847, ECO:0000269|PubMed:17333334, ECO:0000269|PubMed:17565987, ECO:0000269|PubMed:17693412, ECO:0000269|PubMed:18836454, ECO:0000269|PubMed:19949837, ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:21085490, ECO:0000269|PubMed:21423175, ECO:0000269|PubMed:21514275, ECO:0000269|PubMed:21812984, ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:33934390}.; FUNCTION: [Isoform 2]: Phosphorylates and activates ABL1 in sperm flagellum to promote spermatozoa capacitation. {ECO:0000250|UniProtKB:P05132}. |
P20340 | RAB6A | S23 | ochoa | Ras-related protein Rab-6A (Rab-6) (EC 3.6.5.2) | The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes (PubMed:25962623). Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:25962623). RAB6A acts as a regulator of COPI-independent retrograde transport from the Golgi apparatus towards the endoplasmic reticulum (ER) (PubMed:25962623). Has a low GTPase activity (PubMed:25962623). Recruits VPS13B to the Golgi membrane (PubMed:25492866). Plays a role in neuron projection development (Probable). {ECO:0000269|PubMed:25492866, ECO:0000269|PubMed:25962623, ECO:0000305|PubMed:25492866}. |
P21127 | CDK11B | T448 | ochoa | Cyclin-dependent kinase 11B (EC 2.7.11.22) (Cell division cycle 2-like protein kinase 1) (CLK-1) (Cell division protein kinase 11B) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L1) (p58 CLK-1) | Plays multiple roles in cell cycle progression, cytokinesis and apoptosis. Involved in pre-mRNA splicing in a kinase activity-dependent manner. Isoform 7 may act as a negative regulator of normal cell cycle progression. {ECO:0000269|PubMed:12501247, ECO:0000269|PubMed:12624090, ECO:0000269|PubMed:18216018, ECO:0000269|PubMed:2217177}. |
P22694 | PRKACB | S54 | ochoa | cAMP-dependent protein kinase catalytic subunit beta (PKA C-beta) (EC 2.7.11.11) | Mediates cAMP-dependent signaling triggered by receptor binding to GPCRs (PubMed:12420224, PubMed:21423175, PubMed:31112131). PKA activation regulates diverse cellular processes such as cell proliferation, the cell cycle, differentiation and regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear envelope disassembly and reassembly, as well as regulation of intracellular transport mechanisms and ion flux (PubMed:12420224, PubMed:21423175). Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis (PubMed:12420224, PubMed:21423175). Phosphorylates GPKOW which regulates its ability to bind RNA (PubMed:21880142). Acts as a negative regulator of mTORC1 by mediating phosphorylation of RPTOR (PubMed:31112131). {ECO:0000269|PubMed:12420224, ECO:0000269|PubMed:21423175, ECO:0000269|PubMed:21880142, ECO:0000269|PubMed:31112131}. |
P31323 | PRKAR2B | S220 | ochoa | cAMP-dependent protein kinase type II-beta regulatory subunit | Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase. |
P48634 | PRRC2A | S46 | ochoa | Protein PRRC2A (HLA-B-associated transcript 2) (Large proline-rich protein BAT2) (Proline-rich and coiled-coil-containing protein 2A) (Protein G2) | May play a role in the regulation of pre-mRNA splicing. {ECO:0000269|PubMed:14667819}. |
P51812 | RPS6KA3 | S78 | ochoa | Ribosomal protein S6 kinase alpha-3 (S6K-alpha-3) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 3) (p90-RSK 3) (p90RSK3) (Insulin-stimulated protein kinase 1) (ISPK-1) (MAP kinase-activated protein kinase 1b) (MAPK-activated protein kinase 1b) (MAPKAP kinase 1b) (MAPKAPK-1b) (Ribosomal S6 kinase 2) (RSK-2) (pp90RSK2) | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:16213824, PubMed:16223362, PubMed:17360704, PubMed:9770464). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:10436156, PubMed:9770464). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (PubMed:18508509, PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:18722121). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (By similarity). In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity). Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). Acts as a regulator of osteoblast differentiation by mediating phosphorylation of ATF4, thereby promoting ATF4 transactivation activity (By similarity). {ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156, ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362, ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121, ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835, ECO:0000269|PubMed:9770464, ECO:0000303|PubMed:18508509, ECO:0000303|PubMed:18813292}. |
P60709 | ACTB | Y53 | ochoa|psp | Actin, cytoplasmic 1 (EC 3.6.4.-) (Beta-actin) [Cleaved into: Actin, cytoplasmic 1, N-terminally processed] | Actin is a highly conserved protein that polymerizes to produce filaments that form cross-linked networks in the cytoplasm of cells (PubMed:25255767, PubMed:29581253). Actin exists in both monomeric (G-actin) and polymeric (F-actin) forms, both forms playing key functions, such as cell motility and contraction (PubMed:29581253). In addition to their role in the cytoplasmic cytoskeleton, G- and F-actin also localize in the nucleus, and regulate gene transcription and motility and repair of damaged DNA (PubMed:29925947). Plays a role in the assembly of the gamma-tubulin ring complex (gTuRC), which regulates the minus-end nucleation of alpha-beta tubulin heterodimers that grow into microtubule protafilaments (PubMed:39321809, PubMed:38609661). Part of the ACTR1A/ACTB filament around which the dynactin complex is built (By similarity). The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity). {ECO:0000250|UniProtKB:Q6QAQ1, ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:29581253, ECO:0000269|PubMed:29925947, ECO:0000269|PubMed:38609661, ECO:0000269|PubMed:39321809}. |
P62736 | ACTA2 | Y55 | ochoa | Actin, aortic smooth muscle (EC 3.6.4.-) (Alpha-actin-2) (Cell growth-inhibiting gene 46 protein) [Cleaved into: Actin, aortic smooth muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
P63261 | ACTG1 | Y53 | ochoa | Actin, cytoplasmic 2 (EC 3.6.4.-) (Gamma-actin) [Cleaved into: Actin, cytoplasmic 2, N-terminally processed] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. May play a role in the repair of noise-induced stereocilia gaps thereby maintains hearing sensitivity following loud noise damage (By similarity). {ECO:0000250|UniProtKB:P63260, ECO:0000305|PubMed:29581253}. |
P63267 | ACTG2 | Y54 | ochoa | Actin, gamma-enteric smooth muscle (EC 3.6.4.-) (Alpha-actin-3) (Gamma-2-actin) (Smooth muscle gamma-actin) [Cleaved into: Actin, gamma-enteric smooth muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
P68032 | ACTC1 | Y55 | ochoa|psp | Actin, alpha cardiac muscle 1 (EC 3.6.4.-) (Alpha-cardiac actin) [Cleaved into: Actin, alpha cardiac muscle 1, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
P68133 | ACTA1 | Y55 | ochoa | Actin, alpha skeletal muscle (EC 3.6.4.-) (Alpha-actin-1) [Cleaved into: Actin, alpha skeletal muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
P68871 | HBB | S73 | ochoa | Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved into: LVV-hemorphin-7; Spinorphin] | Involved in oxygen transport from the lung to the various peripheral tissues. {ECO:0000269|PubMed:28066926}.; FUNCTION: LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.; FUNCTION: [Spinorphin]: Functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signaling, these properties implicate it as a regulator of pain and inflammation. |
Q00536 | CDK16 | T175 | ochoa|psp | Cyclin-dependent kinase 16 (EC 2.7.11.22) (Cell division protein kinase 16) (PCTAIRE-motif protein kinase 1) (Serine/threonine-protein kinase PCTAIRE-1) | Protein kinase that plays a role in vesicle-mediated transport processes and exocytosis. Regulates GH1 release by brain neurons. Phosphorylates NSF, and thereby regulates NSF oligomerization. Required for normal spermatogenesis. Regulates neuron differentiation and dendrite development (By similarity). Plays a role in the regulation of insulin secretion in response to changes in blood glucose levels. Can phosphorylate CCNY at 'Ser-336' (in vitro). {ECO:0000250, ECO:0000269|PubMed:22184064, ECO:0000269|PubMed:22796189, ECO:0000269|PubMed:22798068}. |
Q00537 | CDK17 | T202 | ochoa | Cyclin-dependent kinase 17 (EC 2.7.11.22) (Cell division protein kinase 17) (PCTAIRE-motif protein kinase 2) (Serine/threonine-protein kinase PCTAIRE-2) | May play a role in terminally differentiated neurons. Has a Ser/Thr-phosphorylating activity for histone H1 (By similarity). {ECO:0000250}. |
Q05655 | PRKCD | S359 | psp | Protein kinase C delta type (EC 2.7.11.13) (Tyrosine-protein kinase PRKCD) (EC 2.7.10.2) (nPKC-delta) [Cleaved into: Protein kinase C delta type regulatory subunit; Protein kinase C delta type catalytic subunit (Sphingosine-dependent protein kinase-1) (SDK1)] | Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses (PubMed:21406692, PubMed:21810427). Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction (By similarity). Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis (PubMed:21406692, PubMed:21810427). In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53 (PubMed:21406692, PubMed:21810427). In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53 (PubMed:21406692, PubMed:21810427). In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation (By similarity). Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1 (PubMed:15774464). Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Involved in antifungal immunity by mediating phosphorylation and activation of CARD9 downstream of C-type lectin receptors activation, promoting interaction between CARD9 and BCL10, followed by activation of NF-kappa-B and MAP kinase p38 pathways (By similarity). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways (PubMed:19801500). May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA (PubMed:11748588). In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation (PubMed:16940418). Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release (PubMed:19587372). Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin (PubMed:11877440). The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By similarity). Phosphorylates ELAVL1 in response to angiotensin-2 treatment (PubMed:18285462). Phosphorylates mitochondrial phospholipid scramblase 3 (PLSCR3), resulting in increased cardiolipin expression on the mitochondrial outer membrane which facilitates apoptosis (PubMed:12649167). Phosphorylates SMPD1 which induces SMPD1 secretion (PubMed:17303575). {ECO:0000250|UniProtKB:P28867, ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12649167, ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418, ECO:0000269|PubMed:17303575, ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372, ECO:0000269|PubMed:19801500, ECO:0000303|PubMed:21406692, ECO:0000303|PubMed:21810427}. |
Q13043 | STK4 | S40 | psp | Serine/threonine-protein kinase 4 (EC 2.7.11.1) (Mammalian STE20-like protein kinase 1) (MST-1) (STE20-like kinase MST1) (Serine/threonine-protein kinase Krs-2) [Cleaved into: Serine/threonine-protein kinase 4 37kDa subunit (MST1/N); Serine/threonine-protein kinase 4 18kDa subunit (MST1/C)] | Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation. Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation (By similarity). Phosphorylates 'Ser-14' of histone H2B (H2BS14ph) during apoptosis. Phosphorylates FOXO3 upon oxidative stress, which results in its nuclear translocation and cell death initiation. Phosphorylates MOBKL1A, MOBKL1B and RASSF2. Phosphorylates TNNI3 (cardiac Tn-I) and alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T). Phosphorylates FOXO1 on 'Ser-212' and regulates its activation and stimulates transcription of PMAIP1 in a FOXO1-dependent manner. Phosphorylates SIRT1 and inhibits SIRT1-mediated p53/TP53 deacetylation, thereby promoting p53/TP53 dependent transcription and apoptosis upon DNA damage. Acts as an inhibitor of PKB/AKT1. Phosphorylates AR on 'Ser-650' and suppresses its activity by intersecting with PKB/AKT1 signaling and antagonizing formation of AR-chromatin complexes. {ECO:0000250|UniProtKB:Q9JI11, ECO:0000269|PubMed:11278283, ECO:0000269|PubMed:11517310, ECO:0000269|PubMed:12757711, ECO:0000269|PubMed:15109305, ECO:0000269|PubMed:16510573, ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:16930133, ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:18328708, ECO:0000269|PubMed:18986304, ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:21212262, ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:21512132, ECO:0000269|PubMed:8702870, ECO:0000269|PubMed:8816758}. |
Q15418 | RPS6KA1 | S72 | ochoa | Ribosomal protein S6 kinase alpha-1 (S6K-alpha-1) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 1) (p90-RSK 1) (p90RSK1) (p90S6K) (MAP kinase-activated protein kinase 1a) (MAPK-activated protein kinase 1a) (MAPKAP kinase 1a) (MAPKAPK-1a) (Ribosomal S6 kinase 1) (RSK-1) | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:10679322, PubMed:12213813, PubMed:15117958, PubMed:16223362, PubMed:17360704, PubMed:18722121, PubMed:26158630, PubMed:35772404, PubMed:9430688). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:18508509, PubMed:18813292). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:12213813, PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:18508509, PubMed:18813292). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the pre-initiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (PubMed:16763566). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:15342917). Also involved in feedback regulation of mTORC1 and mTORC2 by phosphorylating DEPTOR (PubMed:22017876). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:10679322, PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:11684016). Mediates induction of hepatocyte prolifration by TGFA through phosphorylation of CEBPB (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (PubMed:18508509, PubMed:18813292). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). In response to mTORC1 activation, phosphorylates EIF4B at 'Ser-406' and 'Ser-422' which stimulates bicarbonate cotransporter SLC4A7 mRNA translation, increasing SLC4A7 protein abundance and function (PubMed:35772404). {ECO:0000269|PubMed:10679322, ECO:0000269|PubMed:11684016, ECO:0000269|PubMed:12213813, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:15342917, ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362, ECO:0000269|PubMed:16763566, ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121, ECO:0000269|PubMed:22017876, ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:35772404, ECO:0000269|PubMed:9430688, ECO:0000303|PubMed:18508509, ECO:0000303|PubMed:18813292}.; FUNCTION: (Microbial infection) Promotes the late transcription and translation of viral lytic genes during Kaposi's sarcoma-associated herpesvirus/HHV-8 infection, when constitutively activated. {ECO:0000269|PubMed:30842327}. |
Q5JSZ5 | PRRC2B | S47 | ochoa | Protein PRRC2B (HLA-B-associated transcript 2-like 1) (Proline-rich coiled-coil protein 2B) | None |
Q99640 | PKMYT1 | S120 | ochoa | Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (EC 2.7.11.1) (Myt1 kinase) | Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins (PubMed:10373560, PubMed:10504341, PubMed:9001210, PubMed:9268380). Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation (PubMed:9001210, PubMed:9268380). May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect (PubMed:9001210, PubMed:9268380). {ECO:0000269|PubMed:10373560, ECO:0000269|PubMed:10504341, ECO:0000269|PubMed:9001210, ECO:0000269|PubMed:9268380}. |
Q9NRW1 | RAB6B | S23 | ochoa | Ras-related protein Rab-6B (EC 3.6.5.2) | The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between active GTP-bound and inactive GDP-bound states. In their active state, drive transport of vesicular carriers from donor organelles to acceptor organelles to regulate the membrane traffic that maintains organelle identity and morphology (By similarity). Recruits VPS13B to the Golgi membrane (PubMed:25492866). Regulates the compacted morphology of the Golgi (PubMed:26209634). Seems to have a role in retrograde membrane traffic at the level of the Golgi complex. May function in retrograde transport in neuronal cells (PubMed:17707369). Plays a role in neuron projection development (PubMed:25492866). {ECO:0000250|UniProtKB:P20340, ECO:0000269|PubMed:17707369, ECO:0000269|PubMed:25492866, ECO:0000269|PubMed:26209634}. |
Q9P289 | STK26 | S34 | ochoa | Serine/threonine-protein kinase 26 (EC 2.7.11.1) (MST3 and SOK1-related kinase) (Mammalian STE20-like protein kinase 4) (MST-4) (STE20-like kinase MST4) (Serine/threonine-protein kinase MASK) | Serine/threonine-protein kinase that acts as a mediator of cell growth (PubMed:11641781, PubMed:17360971). Modulates apoptosis (PubMed:11641781, PubMed:17360971). In association with STK24 negatively regulates Golgi reorientation in polarized cell migration upon RHO activation (PubMed:27807006). Phosphorylates ATG4B at 'Ser-383', thereby increasing autophagic flux (PubMed:29232556). Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation (PubMed:18782753). {ECO:0000269|PubMed:11641781, ECO:0000269|PubMed:17360971, ECO:0000269|PubMed:18782753, ECO:0000269|PubMed:27807006, ECO:0000269|PubMed:29232556}. |
Q9UK32 | RPS6KA6 | S83 | ochoa | Ribosomal protein S6 kinase alpha-6 (S6K-alpha-6) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 6) (p90-RSK 6) (p90RSK6) (Ribosomal S6 kinase 4) (RSK-4) (pp90RSK4) | Constitutively active serine/threonine-protein kinase that exhibits growth-factor-independent kinase activity and that may participate in p53/TP53-dependent cell growth arrest signaling and play an inhibitory role during embryogenesis. {ECO:0000269|PubMed:15042092, ECO:0000269|PubMed:15632195}. |
Q9UQ88 | CDK11A | T436 | ochoa | Cyclin-dependent kinase 11A (EC 2.7.11.22) (Cell division cycle 2-like protein kinase 2) (Cell division protein kinase 11A) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L2) | Appears to play multiple roles in cell cycle progression, cytokinesis and apoptosis. The p110 isoforms have been suggested to be involved in pre-mRNA splicing, potentially by phosphorylating the splicing protein SFRS7. The p58 isoform may act as a negative regulator of normal cell cycle progression. {ECO:0000269|PubMed:12501247, ECO:0000269|PubMed:12624090}. |
Q9Y520 | PRRC2C | S44 | ochoa | Protein PRRC2C (BAT2 domain-containing protein 1) (HBV X-transactivated gene 2 protein) (HBV XAg-transactivated protein 2) (HLA-B-associated transcript 2-like 2) (Proline-rich and coiled-coil-containing protein 2C) | Required for efficient formation of stress granules. {ECO:0000269|PubMed:29395067}. |
O00506 | STK25 | S30 | Sugiyama | Serine/threonine-protein kinase 25 (EC 2.7.11.1) (Ste20-like kinase) (Sterile 20/oxidant stress-response kinase 1) (SOK-1) (Ste20/oxidant stress response kinase 1) | Oxidant stress-activated serine/threonine kinase that may play a role in the response to environmental stress. Targets to the Golgi apparatus where it appears to regulate protein transport events, cell adhesion, and polarity complexes important for cell migration. Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation (PubMed:18782753). {ECO:0000269|PubMed:15037601, ECO:0000269|PubMed:18782753}. |
O15357 | INPPL1 | S189 | Sugiyama | Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 (EC 3.1.3.86) (Inositol polyphosphate phosphatase-like protein 1) (INPPL-1) (Protein 51C) (SH2 domain-containing inositol 5'-phosphatase 2) (SH2 domain-containing inositol phosphatase 2) (SHIP-2) | Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways (PubMed:16824732). Required for correct mitotic spindle orientation and therefore progression of mitosis (By similarity). Plays a central role in regulation of PI3K-dependent insulin signaling, although the precise molecular mechanisms and signaling pathways remain unclear (PubMed:9660833). While overexpression reduces both insulin-stimulated MAP kinase and Akt activation, its absence does not affect insulin signaling or GLUT4 trafficking (By similarity). Confers resistance to dietary obesity (By similarity). May act by regulating AKT2, but not AKT1, phosphorylation at the plasma membrane (By similarity). Part of a signaling pathway that regulates actin cytoskeleton remodeling (PubMed:11739414, PubMed:12676785). Required for the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation (PubMed:15668240). Participates in regulation of cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling (PubMed:21624956). Regulates cell adhesion and cell spreading (PubMed:12235291). Required for HGF-mediated lamellipodium formation, cell scattering and spreading (PubMed:15735664). Acts as a negative regulator of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1 activation (PubMed:17135240). Acts as a regulator of neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required to form an initial protrusive pattern, and later, maintain proper neurite outgrowth (By similarity). Acts as a negative regulator of the FC-gamma-RIIA receptor (FCGR2A) (PubMed:12690104). Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems (PubMed:11016922). Involved in EGF signaling pathway (PubMed:11349134). Upon stimulation by EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3 (PubMed:11349134). Plays a negative role in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity (PubMed:11349134). Down-regulates Fc-gamma-R-mediated phagocytosis in macrophages independently of INPP5D/SHIP1 (By similarity). In macrophages, down-regulates NF-kappa-B-dependent gene transcription by regulating macrophage colony-stimulating factor (M-CSF)-induced signaling (By similarity). Plays a role in the localization of AURKA and NEDD9/HEF1 to the basolateral membrane at interphase in polarized cysts, thereby mediates cell cycle homeostasis, cell polarization and cilia assembly (By similarity). Additionally promotion of cilia growth is also facilitated by hydrolysis of (PtdIns(3,4,5)P3) to PtdIns(3,4)P2 (By similarity). Promotes formation of apical membrane-initiation sites during the initial stages of lumen formation via Rho family-induced actin filament organization and CTNNB1 localization to cell-cell contacts (By similarity). May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6. Involved in endochondral ossification (PubMed:23273569). {ECO:0000250|UniProtKB:F1PNY0, ECO:0000250|UniProtKB:Q6P549, ECO:0000250|UniProtKB:Q9WVR3, ECO:0000269|PubMed:11016922, ECO:0000269|PubMed:11349134, ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:12235291, ECO:0000269|PubMed:12676785, ECO:0000269|PubMed:12690104, ECO:0000269|PubMed:15668240, ECO:0000269|PubMed:15735664, ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:21624956, ECO:0000269|PubMed:23273569, ECO:0000269|PubMed:9660833}. |
P14616 | INSRR | S989 | Sugiyama | Insulin receptor-related protein (IRR) (EC 2.7.10.1) (IR-related receptor) [Cleaved into: Insulin receptor-related protein alpha chain; Insulin receptor-related protein beta chain] | Receptor with tyrosine-protein kinase activity. Functions as a pH sensing receptor which is activated by increased extracellular pH. Activates an intracellular signaling pathway that involves IRS1 and AKT1/PKB. {ECO:0000269|PubMed:21641549}. |
P22612 | PRKACG | S54 | Sugiyama | cAMP-dependent protein kinase catalytic subunit gamma (PKA C-gamma) (EC 2.7.11.11) | Phosphorylates a large number of substrates in the cytoplasm and the nucleus. |
P49760 | CLK2 | T173 | Sugiyama | Dual specificity protein kinase CLK2 (EC 2.7.12.1) (CDC-like kinase 2) | Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Acts as a suppressor of hepatic gluconeogenesis and glucose output by repressing PPARGC1A transcriptional activity on gluconeogenic genes via its phosphorylation. Phosphorylates PPP2R5B thereby stimulating the assembly of PP2A phosphatase with the PPP2R5B-AKT1 complex leading to dephosphorylation of AKT1. Phosphorylates: PTPN1, SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Phosphorylates PAGE4 at several serine and threonine residues and this phosphorylation attenuates the ability of PAGE4 to potentiate the transcriptional activator activity of JUN (PubMed:28289210). {ECO:0000269|PubMed:10480872, ECO:0000269|PubMed:19168442, ECO:0000269|PubMed:28289210, ECO:0000269|PubMed:8910305, ECO:0000269|PubMed:9637771}. |
P50750 | CDK9 | T29 | Sugiyama | Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE) (Tat-associated kinase complex catalytic subunit) | Protein kinase involved in the regulation of transcription (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094, PubMed:29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:16427012, PubMed:20930849, PubMed:28426094, PubMed:30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed:10912001, PubMed:11112772, PubMed:12037670, PubMed:16427012, PubMed:20081228, PubMed:20980437, PubMed:21127351, PubMed:9857195). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed:17956865, PubMed:18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed:10393184, PubMed:11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed:15564463, PubMed:19575011, PubMed:19844166). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed:15564463, PubMed:19575011, PubMed:19844166). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed:20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed:20493174). Promotes cardiac myocyte enlargement (PubMed:20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed:21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed:10912001, PubMed:11112772, PubMed:9857195). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed:12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed:29335245). {ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10574912, ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001, ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11145967, ECO:0000269|PubMed:11575923, ECO:0000269|PubMed:11809800, ECO:0000269|PubMed:11884399, ECO:0000269|PubMed:12037670, ECO:0000269|PubMed:14701750, ECO:0000269|PubMed:15564463, ECO:0000269|PubMed:16109376, ECO:0000269|PubMed:16109377, ECO:0000269|PubMed:16427012, ECO:0000269|PubMed:17956865, ECO:0000269|PubMed:18362169, ECO:0000269|PubMed:19575011, ECO:0000269|PubMed:19844166, ECO:0000269|PubMed:20081228, ECO:0000269|PubMed:20493174, ECO:0000269|PubMed:20930849, ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21127351, ECO:0000269|PubMed:28426094, ECO:0000269|PubMed:29335245, ECO:0000269|PubMed:30134174, ECO:0000269|PubMed:9857195}. |
Q12851 | MAP4K2 | T26 | Sugiyama | Mitogen-activated protein kinase kinase kinase kinase 2 (EC 2.7.11.1) (B lymphocyte serine/threonine-protein kinase) (Germinal center kinase) (GC kinase) (MAPK/ERK kinase kinase kinase 2) (MEK kinase kinase 2) (MEKKK 2) (Rab8-interacting protein) | Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Also mediates the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion. Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443). {ECO:0000269|PubMed:11784851, ECO:0000269|PubMed:15456887, ECO:0000269|PubMed:17584736, ECO:0000269|PubMed:26437443, ECO:0000269|PubMed:7477268, ECO:0000269|PubMed:7515885, ECO:0000269|PubMed:9712898}. |
Q13188 | STK3 | S37 | Sugiyama | Serine/threonine-protein kinase 3 (EC 2.7.11.1) (Mammalian STE20-like protein kinase 2) (MST-2) (STE20-like kinase MST2) (Serine/threonine-protein kinase Krs-1) [Cleaved into: Serine/threonine-protein kinase 3 36kDa subunit (MST2/N); Serine/threonine-protein kinase 3 20kDa subunit (MST2/C)] | Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation (PubMed:11278283, PubMed:8566796, PubMed:8816758). Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ (PubMed:15688006, PubMed:16930133, PubMed:23972470, PubMed:28087714, PubMed:29063833, PubMed:30622739). Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration (PubMed:15688006, PubMed:16930133, PubMed:23972470, PubMed:28087714). STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation. Phosphorylates NKX2-1 (By similarity). Phosphorylates NEK2 and plays a role in centrosome disjunction by regulating the localization of NEK2 to centrosome, and its ability to phosphorylate CROCC and CEP250 (PubMed:21076410, PubMed:21723128). In conjunction with SAV1, activates the transcriptional activity of ESR1 through the modulation of its phosphorylation (PubMed:21104395). Positively regulates RAF1 activation via suppression of the inhibitory phosphorylation of RAF1 on 'Ser-259' (PubMed:20212043). Phosphorylates MOBKL1A and RASSF2 (PubMed:19525978). Phosphorylates MOBKL1B on 'Thr-74'. Acts cooperatively with MOBKL1B to activate STK38 (PubMed:18328708, PubMed:18362890). {ECO:0000250|UniProtKB:Q9JI10, ECO:0000269|PubMed:11278283, ECO:0000269|PubMed:15688006, ECO:0000269|PubMed:16930133, ECO:0000269|PubMed:18328708, ECO:0000269|PubMed:18362890, ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:20212043, ECO:0000269|PubMed:21076410, ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21723128, ECO:0000269|PubMed:23972470, ECO:0000269|PubMed:28087714, ECO:0000269|PubMed:29063833, ECO:0000269|PubMed:30622739, ECO:0000269|PubMed:8566796, ECO:0000269|PubMed:8816758}. |
Q8NG66 | NEK11 | S39 | Sugiyama | Serine/threonine-protein kinase Nek11 (EC 2.7.11.1) (Never in mitosis A-related kinase 11) (NimA-related protein kinase 11) | Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation. {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:19734889, ECO:0000269|PubMed:20090422}. |
Q99558 | MAP3K14 | S410 | Sugiyama | Mitogen-activated protein kinase kinase kinase 14 (EC 2.7.11.25) (NF-kappa-beta-inducing kinase) (HsNIK) (Serine/threonine-protein kinase NIK) | Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity. Phosphorylates CHUK/IKKA, thereby promoting proteolytic processing of NFKB2/P100, which leads to NF-kappa-B activation via the non-canonical pathway (PubMed:25406581, PubMed:29230214). Has an essential role in the non-canonical NF-kappa-B signaling that regulates genes encoding molecules involved in B-cell survival, lymphoid organogenesis, and immune response (PubMed:25406581). Could act in a receptor-selective manner. {ECO:0000269|PubMed:15084608, ECO:0000269|PubMed:25406581}. |
Q6ZN16 | MAP3K15 | T662 | Sugiyama | Mitogen-activated protein kinase kinase kinase 15 (EC 2.7.11.25) (Apoptosis signal-regulating kinase 3) (MAPK/ERK kinase kinase 15) (MEK kinase 15) (MEKK 15) | Serine/threonine kinase which acts as a component of the MAP kinase signal transduction pathway (PubMed:20362554, PubMed:26732173). Once activated, acts as an upstream activator of the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases (PubMed:20362554, PubMed:26732173). May function in a signal transduction pathway that is activated by various cell stresses and leads to apoptosis (PubMed:20362554). Involved in phosphorylation of WNK4 in response to osmotic stress or hypotonic low-chloride stimulation via the p38 MAPK signal transduction cascade (PubMed:26732173). {ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}. |
Q99683 | MAP3K5 | T690 | Sugiyama | Mitogen-activated protein kinase kinase kinase 5 (EC 2.7.11.25) (Apoptosis signal-regulating kinase 1) (ASK-1) (MAPK/ERK kinase kinase 5) (MEK kinase 5) (MEKK 5) | Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signaling for determination of cell fate such as differentiation and survival. Plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. MAP3K5/ASK1 is required for the innate immune response, which is essential for host defense against a wide range of pathogens. Mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals, such as the tumor necrosis factor (TNF) or lipopolysaccharide (LPS). Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K4/SEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs). Both p38 MAPK and JNKs control the transcription factors activator protein-1 (AP-1). {ECO:0000269|PubMed:10411906, ECO:0000269|PubMed:10688666, ECO:0000269|PubMed:10849426, ECO:0000269|PubMed:11029458, ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11689443, ECO:0000269|PubMed:11920685, ECO:0000269|PubMed:14688258, ECO:0000269|PubMed:14749717, ECO:0000269|PubMed:15023544, ECO:0000269|PubMed:16129676, ECO:0000269|PubMed:17220297, ECO:0000269|PubMed:23102700, ECO:0000269|PubMed:26095851, ECO:0000269|PubMed:8940179, ECO:0000269|PubMed:8974401, ECO:0000269|PubMed:9564042, ECO:0000269|PubMed:9774977}. |
Q9Y6E0 | STK24 | S46 | Sugiyama | Serine/threonine-protein kinase 24 (EC 2.7.11.1) (Mammalian STE20-like protein kinase 3) (MST-3) (STE20-like kinase MST3) [Cleaved into: Serine/threonine-protein kinase 24 36 kDa subunit (Mammalian STE20-like protein kinase 3 N-terminal) (MST3/N); Serine/threonine-protein kinase 24 12 kDa subunit (Mammalian STE20-like protein kinase 3 C-terminal) (MST3/C)] | Serine/threonine-protein kinase that acts on both serine and threonine residues and promotes apoptosis in response to stress stimuli and caspase activation. Mediates oxidative-stress-induced cell death by modulating phosphorylation of JNK1-JNK2 (MAPK8 and MAPK9), p38 (MAPK11, MAPK12, MAPK13 and MAPK14) during oxidative stress. Plays a role in a staurosporine-induced caspase-independent apoptotic pathway by regulating the nuclear translocation of AIFM1 and ENDOG and the DNase activity associated with ENDOG. Phosphorylates STK38L on 'Thr-442' and stimulates its kinase activity. In association with STK26 negatively regulates Golgi reorientation in polarized cell migration upon RHO activation (PubMed:27807006). Also regulates cellular migration with alteration of PTPN12 activity and PXN phosphorylation: phosphorylates PTPN12 and inhibits its activity and may regulate PXN phosphorylation through PTPN12. May act as a key regulator of axon regeneration in the optic nerve and radial nerve. Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation (PubMed:18782753). {ECO:0000269|PubMed:16314523, ECO:0000269|PubMed:17046825, ECO:0000269|PubMed:18782753, ECO:0000269|PubMed:19604147, ECO:0000269|PubMed:19782762, ECO:0000269|PubMed:19855390, ECO:0000269|PubMed:27807006}. |
Q7L7X3 | TAOK1 | S38 | Sugiyama | Serine/threonine-protein kinase TAO1 (EC 2.7.11.1) (Kinase from chicken homolog B) (hKFC-B) (MARK Kinase) (MARKK) (Prostate-derived sterile 20-like kinase 2) (PSK-2) (PSK2) (Prostate-derived STE20-like kinase 2) (Thousand and one amino acid protein kinase 1) (TAOK1) (hTAOK1) | Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade. Plays an essential role in the regulation of neuronal development in the central nervous system (PubMed:33565190). Also plays a role in the regulation of neuronal migration to the cortical plate (By similarity). {ECO:0000250|UniProtKB:Q5F2E8, ECO:0000269|PubMed:12665513, ECO:0000269|PubMed:13679851, ECO:0000269|PubMed:16407310, ECO:0000269|PubMed:17396146, ECO:0000269|PubMed:17900936, ECO:0000269|PubMed:33565190}. |
Q9UL54 | TAOK2 | S38 | Sugiyama | Serine/threonine-protein kinase TAO2 (EC 2.7.11.1) (Kinase from chicken homolog C) (hKFC-C) (Prostate-derived sterile 20-like kinase 1) (PSK-1) (PSK1) (Prostate-derived STE20-like kinase 1) (Thousand and one amino acid protein kinase 2) | Serine/threonine-protein kinase involved in different processes such as membrane blebbing and apoptotic bodies formation DNA damage response and MAPK14/p38 MAPK stress-activated MAPK cascade. Phosphorylates itself, MBP, activated MAPK8, MAP2K3, MAP2K6 and tubulins. Activates the MAPK14/p38 MAPK signaling pathway through the specific activation and phosphorylation of the upstream MAP2K3 and MAP2K6 kinases. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of upstream MAP2K3 and MAP2K6 kinases. Isoform 1, but not isoform 2, plays a role in apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation. This function, which requires the activation of MAPK8/JNK and nuclear localization of C-terminally truncated isoform 1, may be linked to the mitochondrial CASP9-associated death pathway. Isoform 1 binds to microtubules and affects their organization and stability independently of its kinase activity. Prevents MAP3K7-mediated activation of CHUK, and thus NF-kappa-B activation, but not that of MAPK8/JNK. May play a role in the osmotic stress-MAPK8 pathway. Isoform 2, but not isoform 1, is required for PCDH8 endocytosis. Following homophilic interactions between PCDH8 extracellular domains, isoform 2 phosphorylates and activates MAPK14/p38 MAPK which in turn phosphorylates isoform 2. This process leads to PCDH8 endocytosis and CDH2 cointernalization. Both isoforms are involved in MAPK14 phosphorylation. {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:12639963, ECO:0000269|PubMed:12665513, ECO:0000269|PubMed:13679851, ECO:0000269|PubMed:16893890, ECO:0000269|PubMed:17158878, ECO:0000269|PubMed:17396146}. |
Download
reactome_id | name | p | -log10_p |
---|---|---|---|
R-HSA-111933 | Calmodulin induced events | 2.002301e-10 | 9.698 |
R-HSA-111997 | CaM pathway | 2.002301e-10 | 9.698 |
R-HSA-9010642 | ROBO receptors bind AKAP5 | 5.519060e-10 | 9.258 |
R-HSA-111996 | Ca-dependent events | 5.648606e-10 | 9.248 |
R-HSA-1489509 | DAG and IP3 signaling | 8.425800e-10 | 9.074 |
R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | 1.383406e-09 | 8.859 |
R-HSA-438064 | Post NMDA receptor activation events | 1.756989e-09 | 8.755 |
R-HSA-442720 | CREB1 phosphorylation through the activation of Adenylate Cyclase | 4.789290e-09 | 8.320 |
R-HSA-112043 | PLC beta mediated events | 5.118099e-09 | 8.291 |
R-HSA-9913351 | Formation of the dystrophin-glycoprotein complex (DGC) | 4.329780e-09 | 8.364 |
R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 6.188994e-09 | 8.208 |
R-HSA-112040 | G-protein mediated events | 9.029214e-09 | 8.044 |
R-HSA-163615 | PKA activation | 2.136936e-08 | 7.670 |
R-HSA-164378 | PKA activation in glucagon signalling | 2.136936e-08 | 7.670 |
R-HSA-4420097 | VEGFA-VEGFR2 Pathway | 1.711002e-08 | 7.767 |
R-HSA-3000171 | Non-integrin membrane-ECM interactions | 1.796836e-08 | 7.745 |
R-HSA-194138 | Signaling by VEGF | 3.197884e-08 | 7.495 |
R-HSA-111931 | PKA-mediated phosphorylation of CREB | 3.913654e-08 | 7.407 |
R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 1.099284e-07 | 6.959 |
R-HSA-9764561 | Regulation of CDH1 Function | 1.181341e-07 | 6.928 |
R-HSA-111885 | Opioid Signalling | 1.617341e-07 | 6.791 |
R-HSA-180024 | DARPP-32 events | 1.689457e-07 | 6.772 |
R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 2.095882e-07 | 6.679 |
R-HSA-163359 | Glucagon signaling in metabolic regulation | 3.250729e-07 | 6.488 |
R-HSA-381676 | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 9.662306e-07 | 6.015 |
R-HSA-9660821 | ADORA2B mediated anti-inflammatory cytokines production | 1.282849e-06 | 5.892 |
R-HSA-432040 | Vasopressin regulates renal water homeostasis via Aquaporins | 1.282849e-06 | 5.892 |
R-HSA-437239 | Recycling pathway of L1 | 1.535749e-06 | 5.814 |
R-HSA-9634597 | GPER1 signaling | 1.676109e-06 | 5.776 |
R-HSA-392517 | Rap1 signalling | 1.703407e-06 | 5.769 |
R-HSA-422356 | Regulation of insulin secretion | 2.336734e-06 | 5.631 |
R-HSA-112315 | Transmission across Chemical Synapses | 2.765131e-06 | 5.558 |
R-HSA-109582 | Hemostasis | 3.016578e-06 | 5.520 |
R-HSA-163358 | PKA-mediated phosphorylation of key metabolic factors | 3.332502e-06 | 5.477 |
R-HSA-422475 | Axon guidance | 3.478665e-06 | 5.459 |
R-HSA-5621575 | CD209 (DC-SIGN) signaling | 4.094843e-06 | 5.388 |
R-HSA-445717 | Aquaporin-mediated transport | 4.599695e-06 | 5.337 |
R-HSA-9675108 | Nervous system development | 6.336616e-06 | 5.198 |
R-HSA-444257 | RSK activation | 8.599354e-06 | 5.066 |
R-HSA-162582 | Signal Transduction | 9.753165e-06 | 5.011 |
R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 9.935258e-06 | 5.003 |
R-HSA-380287 | Centrosome maturation | 1.116495e-05 | 4.952 |
R-HSA-163685 | Integration of energy metabolism | 1.589886e-05 | 4.799 |
R-HSA-9856530 | High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR... | 1.476252e-05 | 4.831 |
R-HSA-8853659 | RET signaling | 1.671365e-05 | 4.777 |
R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | 1.827634e-05 | 4.738 |
R-HSA-9656223 | Signaling by RAF1 mutants | 2.775033e-05 | 4.557 |
R-HSA-5674135 | MAP2K and MAPK activation | 2.775033e-05 | 4.557 |
R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | 4.040787e-05 | 4.394 |
R-HSA-9649948 | Signaling downstream of RAS mutants | 4.040787e-05 | 4.394 |
R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | 4.040787e-05 | 4.394 |
R-HSA-6802949 | Signaling by RAS mutants | 4.040787e-05 | 4.394 |
R-HSA-5683057 | MAPK family signaling cascades | 3.896022e-05 | 4.409 |
R-HSA-8963896 | HDL assembly | 3.703510e-05 | 4.431 |
R-HSA-9006925 | Intracellular signaling by second messengers | 3.537979e-05 | 4.451 |
R-HSA-5610787 | Hedgehog 'off' state | 4.436748e-05 | 4.353 |
R-HSA-112316 | Neuronal System | 4.564769e-05 | 4.341 |
R-HSA-9634600 | Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 5.055297e-05 | 4.296 |
R-HSA-9860931 | Response of endothelial cells to shear stress | 5.240435e-05 | 4.281 |
R-HSA-5621481 | C-type lectin receptors (CLRs) | 5.284521e-05 | 4.277 |
R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | 5.597342e-05 | 4.252 |
R-HSA-9764265 | Regulation of CDH1 Expression and Function | 5.597342e-05 | 4.252 |
R-HSA-69275 | G2/M Transition | 8.010998e-05 | 4.096 |
R-HSA-9855142 | Cellular responses to mechanical stimuli | 8.038247e-05 | 4.095 |
R-HSA-9658195 | Leishmania infection | 8.286340e-05 | 4.082 |
R-HSA-9824443 | Parasitic Infection Pathways | 8.286340e-05 | 4.082 |
R-HSA-453274 | Mitotic G2-G2/M phases | 8.446491e-05 | 4.073 |
R-HSA-881907 | Gastrin-CREB signalling pathway via PKC and MAPK | 8.649942e-05 | 4.063 |
R-HSA-373760 | L1CAM interactions | 9.299416e-05 | 4.032 |
R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | 1.038122e-04 | 3.984 |
R-HSA-6802952 | Signaling by BRAF and RAF1 fusions | 1.285123e-04 | 3.891 |
R-HSA-9664323 | FCGR3A-mediated IL10 synthesis | 1.356034e-04 | 3.868 |
R-HSA-8963898 | Plasma lipoprotein assembly | 1.664682e-04 | 3.779 |
R-HSA-5358351 | Signaling by Hedgehog | 2.098211e-04 | 3.678 |
R-HSA-418990 | Adherens junctions interactions | 1.796920e-04 | 3.745 |
R-HSA-1474244 | Extracellular matrix organization | 2.126052e-04 | 3.672 |
R-HSA-6802957 | Oncogenic MAPK signaling | 3.215561e-04 | 3.493 |
R-HSA-5687128 | MAPK6/MAPK4 signaling | 3.215561e-04 | 3.493 |
R-HSA-111465 | Apoptotic cleavage of cellular proteins | 3.317233e-04 | 3.479 |
R-HSA-442742 | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 3.577270e-04 | 3.446 |
R-HSA-421270 | Cell-cell junction organization | 3.587569e-04 | 3.445 |
R-HSA-5674499 | Negative feedback regulation of MAPK pathway | 3.733594e-04 | 3.428 |
R-HSA-199920 | CREB phosphorylation | 4.714798e-04 | 3.327 |
R-HSA-163560 | Triglyceride catabolism | 4.747837e-04 | 3.324 |
R-HSA-418555 | G alpha (s) signalling events | 5.296990e-04 | 3.276 |
R-HSA-9664433 | Leishmania parasite growth and survival | 5.552480e-04 | 3.256 |
R-HSA-9662851 | Anti-inflammatory response favouring Leishmania parasite infection | 5.552480e-04 | 3.256 |
R-HSA-9726840 | SHOC2 M1731 mutant abolishes MRAS complex function | 5.807769e-04 | 3.236 |
R-HSA-446728 | Cell junction organization | 5.903848e-04 | 3.229 |
R-HSA-5610785 | GLI3 is processed to GLI3R by the proteasome | 6.922791e-04 | 3.160 |
R-HSA-5610783 | Degradation of GLI2 by the proteasome | 6.922791e-04 | 3.160 |
R-HSA-5610780 | Degradation of GLI1 by the proteasome | 6.922791e-04 | 3.160 |
R-HSA-418594 | G alpha (i) signalling events | 6.938090e-04 | 3.159 |
R-HSA-196025 | Formation of annular gap junctions | 7.011746e-04 | 3.154 |
R-HSA-9660537 | Signaling by MRAS-complex mutants | 7.011746e-04 | 3.154 |
R-HSA-9726842 | Gain-of-function MRAS complexes activate RAF signaling | 7.011746e-04 | 3.154 |
R-HSA-190873 | Gap junction degradation | 8.325973e-04 | 3.080 |
R-HSA-450520 | HuR (ELAVL1) binds and stabilizes mRNA | 8.325973e-04 | 3.080 |
R-HSA-69278 | Cell Cycle, Mitotic | 9.270403e-04 | 3.033 |
R-HSA-75153 | Apoptotic execution phase | 9.152645e-04 | 3.038 |
R-HSA-1640170 | Cell Cycle | 8.753278e-04 | 3.058 |
R-HSA-376176 | Signaling by ROBO receptors | 1.060620e-03 | 2.974 |
R-HSA-1500931 | Cell-Cell communication | 1.096621e-03 | 2.960 |
R-HSA-397014 | Muscle contraction | 1.287798e-03 | 2.890 |
R-HSA-388396 | GPCR downstream signalling | 1.600514e-03 | 2.796 |
R-HSA-8979227 | Triglyceride metabolism | 1.693375e-03 | 2.771 |
R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centr... | 1.995496e-03 | 2.700 |
R-HSA-380259 | Loss of Nlp from mitotic centrosomes | 1.995496e-03 | 2.700 |
R-HSA-168249 | Innate Immune System | 2.036661e-03 | 2.691 |
R-HSA-446353 | Cell-extracellular matrix interactions | 2.054982e-03 | 2.687 |
R-HSA-8854518 | AURKA Activation by TPX2 | 2.242760e-03 | 2.649 |
R-HSA-2028269 | Signaling by Hippo | 2.736828e-03 | 2.563 |
R-HSA-372790 | Signaling by GPCR | 3.132433e-03 | 2.504 |
R-HSA-198753 | ERK/MAPK targets | 3.788672e-03 | 2.422 |
R-HSA-9013695 | NOTCH4 Intracellular Domain Regulates Transcription | 3.788672e-03 | 2.422 |
R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 4.124267e-03 | 2.385 |
R-HSA-9927432 | Developmental Lineage of Mammary Gland Myoepithelial Cells | 6.729783e-03 | 2.172 |
R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 4.775287e-03 | 2.321 |
R-HSA-5620912 | Anchoring of the basal body to the plasma membrane | 5.052091e-03 | 2.297 |
R-HSA-445095 | Interaction between L1 and Ankyrins | 6.009234e-03 | 2.221 |
R-HSA-5218921 | VEGFR2 mediated cell proliferation | 5.326498e-03 | 2.274 |
R-HSA-68877 | Mitotic Prometaphase | 6.403759e-03 | 2.194 |
R-HSA-450282 | MAPK targets/ Nuclear events mediated by MAP kinases | 6.729783e-03 | 2.172 |
R-HSA-2682334 | EPH-Ephrin signaling | 5.485158e-03 | 2.261 |
R-HSA-8953897 | Cellular responses to stimuli | 6.466992e-03 | 2.189 |
R-HSA-174824 | Plasma lipoprotein assembly, remodeling, and clearance | 5.485158e-03 | 2.261 |
R-HSA-70171 | Glycolysis | 6.915669e-03 | 2.160 |
R-HSA-1250196 | SHC1 events in ERBB2 signaling | 7.104069e-03 | 2.148 |
R-HSA-390522 | Striated Muscle Contraction | 8.693074e-03 | 2.061 |
R-HSA-5673000 | RAF activation | 9.112961e-03 | 2.040 |
R-HSA-176034 | Interactions of Tat with host cellular proteins | 1.037957e-02 | 1.984 |
R-HSA-70326 | Glucose metabolism | 1.082820e-02 | 1.965 |
R-HSA-5675221 | Negative regulation of MAPK pathway | 1.278791e-02 | 1.893 |
R-HSA-68886 | M Phase | 1.302916e-02 | 1.885 |
R-HSA-512988 | Interleukin-3, Interleukin-5 and GM-CSF signaling | 1.328580e-02 | 1.877 |
R-HSA-187037 | Signaling by NTRK1 (TRKA) | 1.368056e-02 | 1.864 |
R-HSA-8854214 | TBC/RABGAPs | 1.379205e-02 | 1.860 |
R-HSA-190828 | Gap junction trafficking | 1.430659e-02 | 1.844 |
R-HSA-3928662 | EPHB-mediated forward signaling | 1.430659e-02 | 1.844 |
R-HSA-1266738 | Developmental Biology | 1.586243e-02 | 1.800 |
R-HSA-6811440 | Retrograde transport at the Trans-Golgi-Network | 1.589934e-02 | 1.799 |
R-HSA-3928665 | EPH-ephrin mediated repulsion of cells | 1.589934e-02 | 1.799 |
R-HSA-157858 | Gap junction trafficking and regulation | 1.700151e-02 | 1.770 |
R-HSA-416476 | G alpha (q) signalling events | 1.717603e-02 | 1.765 |
R-HSA-445355 | Smooth Muscle Contraction | 1.930050e-02 | 1.714 |
R-HSA-166520 | Signaling by NTRKs | 2.024130e-02 | 1.694 |
R-HSA-6811436 | COPI-independent Golgi-to-ER retrograde traffic | 2.049636e-02 | 1.688 |
R-HSA-418597 | G alpha (z) signalling events | 2.049636e-02 | 1.688 |
R-HSA-9662361 | Sensory processing of sound by outer hair cells of the cochlea | 2.110569e-02 | 1.676 |
R-HSA-5673001 | RAF/MAP kinase cascade | 2.259478e-02 | 1.646 |
R-HSA-8873719 | RAB geranylgeranylation | 2.361755e-02 | 1.627 |
R-HSA-1227986 | Signaling by ERBB2 | 2.361755e-02 | 1.627 |
R-HSA-74713 | IRS activation | 2.405455e-02 | 1.619 |
R-HSA-9022535 | Loss of phosphorylation of MECP2 at T308 | 2.405455e-02 | 1.619 |
R-HSA-450294 | MAP kinase activation | 2.426388e-02 | 1.615 |
R-HSA-5684996 | MAPK1/MAPK3 signaling | 2.427951e-02 | 1.615 |
R-HSA-109581 | Apoptosis | 2.494883e-02 | 1.603 |
R-HSA-9732724 | IFNG signaling activates MAPKs | 3.418882e-02 | 1.466 |
R-HSA-114516 | Disinhibition of SNARE formation | 3.418882e-02 | 1.466 |
R-HSA-390450 | Folding of actin by CCT/TriC | 4.421972e-02 | 1.354 |
R-HSA-2428933 | SHC-related events triggered by IGF1R | 5.414828e-02 | 1.266 |
R-HSA-69478 | G2/M DNA replication checkpoint | 3.082227e-02 | 1.511 |
R-HSA-187706 | Signalling to p38 via RIT and RIN | 2.744419e-02 | 1.562 |
R-HSA-170984 | ARMS-mediated activation | 4.088751e-02 | 1.388 |
R-HSA-2179392 | EGFR Transactivation by Gastrin | 4.421972e-02 | 1.354 |
R-HSA-428359 | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RN... | 4.421972e-02 | 1.354 |
R-HSA-9924644 | Developmental Lineages of the Mammary Gland | 3.183851e-02 | 1.497 |
R-HSA-430116 | GP1b-IX-V activation signalling | 4.088751e-02 | 1.388 |
R-HSA-9005891 | Loss of function of MECP2 in Rett syndrome | 5.414828e-02 | 1.266 |
R-HSA-9697154 | Disorders of Nervous System Development | 5.414828e-02 | 1.266 |
R-HSA-9005895 | Pervasive developmental disorders | 5.414828e-02 | 1.266 |
R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 5.369295e-02 | 1.270 |
R-HSA-1247673 | Erythrocytes take up oxygen and release carbon dioxide | 5.414828e-02 | 1.266 |
R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis | 2.980560e-02 | 1.526 |
R-HSA-5617833 | Cilium Assembly | 3.642108e-02 | 1.439 |
R-HSA-9659379 | Sensory processing of sound | 3.708099e-02 | 1.431 |
R-HSA-74749 | Signal attenuation | 4.421972e-02 | 1.354 |
R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 2.898751e-02 | 1.538 |
R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane | 3.256796e-02 | 1.487 |
R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 3.942277e-02 | 1.404 |
R-HSA-450531 | Regulation of mRNA stability by proteins that bind AU-rich elements | 3.183851e-02 | 1.497 |
R-HSA-448424 | Interleukin-17 signaling | 3.039953e-02 | 1.517 |
R-HSA-2559583 | Cellular Senescence | 3.220429e-02 | 1.492 |
R-HSA-9013694 | Signaling by NOTCH4 | 3.330400e-02 | 1.478 |
R-HSA-8876198 | RAB GEFs exchange GTP for GDP on RABs | 4.263049e-02 | 1.370 |
R-HSA-198725 | Nuclear Events (kinase and transcription factor activation) | 3.183851e-02 | 1.497 |
R-HSA-5357801 | Programmed Cell Death | 4.373092e-02 | 1.359 |
R-HSA-975871 | MyD88 cascade initiated on plasma membrane | 5.547685e-02 | 1.256 |
R-HSA-168176 | Toll Like Receptor 5 (TLR5) Cascade | 5.547685e-02 | 1.256 |
R-HSA-168142 | Toll Like Receptor 10 (TLR10) Cascade | 5.547685e-02 | 1.256 |
R-HSA-9933947 | Formation of the non-canonical BAF (ncBAF) complex | 5.743524e-02 | 1.241 |
R-HSA-170968 | Frs2-mediated activation | 5.743524e-02 | 1.241 |
R-HSA-5676594 | TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 5.743524e-02 | 1.241 |
R-HSA-382551 | Transport of small molecules | 5.796117e-02 | 1.237 |
R-HSA-9933937 | Formation of the canonical BAF (cBAF) complex | 6.071097e-02 | 1.217 |
R-HSA-9933939 | Formation of the polybromo-BAF (pBAF) complex | 6.071097e-02 | 1.217 |
R-HSA-1433559 | Regulation of KIT signaling | 6.071097e-02 | 1.217 |
R-HSA-157118 | Signaling by NOTCH | 6.206230e-02 | 1.207 |
R-HSA-168164 | Toll Like Receptor 3 (TLR3) Cascade | 6.281691e-02 | 1.202 |
R-HSA-399954 | Sema3A PAK dependent Axon repulsion | 6.397553e-02 | 1.194 |
R-HSA-9933946 | Formation of the embryonic stem cell BAF (esBAF) complex | 6.397553e-02 | 1.194 |
R-HSA-1295596 | Spry regulation of FGF signaling | 6.397553e-02 | 1.194 |
R-HSA-9734779 | Developmental Cell Lineages of the Integumentary System | 6.565059e-02 | 1.183 |
R-HSA-975138 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 6.565059e-02 | 1.183 |
R-HSA-975155 | MyD88 dependent cascade initiated on endosome | 6.660464e-02 | 1.176 |
R-HSA-169893 | Prolonged ERK activation events | 6.722894e-02 | 1.172 |
R-HSA-5099900 | WNT5A-dependent internalization of FZD4 | 6.722894e-02 | 1.172 |
R-HSA-937061 | TRIF (TICAM1)-mediated TLR4 signaling | 6.756336e-02 | 1.170 |
R-HSA-166166 | MyD88-independent TLR4 cascade | 6.756336e-02 | 1.170 |
R-HSA-5663205 | Infectious disease | 6.930375e-02 | 1.159 |
R-HSA-168181 | Toll Like Receptor 7/8 (TLR7/8) Cascade | 7.046714e-02 | 1.152 |
R-HSA-9927020 | Heme assimilation | 7.047124e-02 | 1.152 |
R-HSA-399997 | Acetylcholine regulates insulin secretion | 7.047124e-02 | 1.152 |
R-HSA-9675151 | Disorders of Developmental Biology | 7.047124e-02 | 1.152 |
R-HSA-69620 | Cell Cycle Checkpoints | 7.268292e-02 | 1.139 |
R-HSA-168138 | Toll Like Receptor 9 (TLR9) Cascade | 7.341146e-02 | 1.134 |
R-HSA-9007101 | Rab regulation of trafficking | 7.639518e-02 | 1.117 |
R-HSA-416993 | Trafficking of GluR2-containing AMPA receptors | 7.692267e-02 | 1.114 |
R-HSA-9613829 | Chaperone Mediated Autophagy | 7.692267e-02 | 1.114 |
R-HSA-4419969 | Depolymerization of the Nuclear Lamina | 7.692267e-02 | 1.114 |
R-HSA-3928664 | Ephrin signaling | 7.692267e-02 | 1.114 |
R-HSA-156711 | Polo-like kinase mediated events | 7.692267e-02 | 1.114 |
R-HSA-166058 | MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 7.840569e-02 | 1.106 |
R-HSA-168188 | Toll Like Receptor TLR6:TLR2 Cascade | 7.840569e-02 | 1.106 |
R-HSA-1237044 | Erythrocytes take up carbon dioxide and release oxygen | 8.013188e-02 | 1.096 |
R-HSA-1480926 | O2/CO2 exchange in erythrocytes | 8.013188e-02 | 1.096 |
R-HSA-1912420 | Pre-NOTCH Processing in Golgi | 8.013188e-02 | 1.096 |
R-HSA-168179 | Toll Like Receptor TLR1:TLR2 Cascade | 8.145267e-02 | 1.089 |
R-HSA-181438 | Toll Like Receptor 2 (TLR2) Cascade | 8.145267e-02 | 1.089 |
R-HSA-76002 | Platelet activation, signaling and aggregation | 8.276410e-02 | 1.082 |
R-HSA-9934037 | Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | 8.333013e-02 | 1.079 |
R-HSA-1280215 | Cytokine Signaling in Immune system | 8.434026e-02 | 1.074 |
R-HSA-8856688 | Golgi-to-ER retrograde transport | 9.399535e-02 | 1.027 |
R-HSA-389957 | Prefoldin mediated transfer of substrate to CCT/TriC | 9.601426e-02 | 1.018 |
R-HSA-912526 | Interleukin receptor SHC signaling | 9.601426e-02 | 1.018 |
R-HSA-3000170 | Syndecan interactions | 9.601426e-02 | 1.018 |
R-HSA-9932444 | ATP-dependent chromatin remodelers | 1.022915e-01 | 0.990 |
R-HSA-9932451 | SWI/SNF chromatin remodelers | 1.022915e-01 | 0.990 |
R-HSA-9664422 | FCGR3A-mediated phagocytosis | 1.037463e-01 | 0.984 |
R-HSA-9664407 | Parasite infection | 1.037463e-01 | 0.984 |
R-HSA-9664417 | Leishmania phagocytosis | 1.037463e-01 | 0.984 |
R-HSA-2029482 | Regulation of actin dynamics for phagocytic cup formation | 1.048466e-01 | 0.979 |
R-HSA-8856828 | Clathrin-mediated endocytosis | 1.081668e-01 | 0.966 |
R-HSA-167243 | Tat-mediated HIV elongation arrest and recovery | 1.085260e-01 | 0.964 |
R-HSA-167238 | Pausing and recovery of Tat-mediated HIV elongation | 1.085260e-01 | 0.964 |
R-HSA-389357 | CD28 dependent PI3K/Akt signaling | 1.085260e-01 | 0.964 |
R-HSA-167287 | HIV elongation arrest and recovery | 1.116272e-01 | 0.952 |
R-HSA-167290 | Pausing and recovery of HIV elongation | 1.116272e-01 | 0.952 |
R-HSA-77387 | Insulin receptor recycling | 1.116272e-01 | 0.952 |
R-HSA-5654732 | Negative regulation of FGFR3 signaling | 1.116272e-01 | 0.952 |
R-HSA-166016 | Toll Like Receptor 4 (TLR4) Cascade | 1.137628e-01 | 0.944 |
R-HSA-9615710 | Late endosomal microautophagy | 1.147179e-01 | 0.940 |
R-HSA-5654733 | Negative regulation of FGFR4 signaling | 1.147179e-01 | 0.940 |
R-HSA-1852241 | Organelle biogenesis and maintenance | 1.148264e-01 | 0.940 |
R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 1.159497e-01 | 0.936 |
R-HSA-389958 | Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 1.208676e-01 | 0.918 |
R-HSA-399719 | Trafficking of AMPA receptors | 1.208676e-01 | 0.918 |
R-HSA-9820960 | Respiratory syncytial virus (RSV) attachment and entry | 1.208676e-01 | 0.918 |
R-HSA-877300 | Interferon gamma signaling | 1.263296e-01 | 0.898 |
R-HSA-399721 | Glutamate binding, activation of AMPA receptors and synaptic plasticity | 1.269753e-01 | 0.896 |
R-HSA-9022692 | Regulation of MECP2 expression and activity | 1.269753e-01 | 0.896 |
R-HSA-5654726 | Negative regulation of FGFR1 signaling | 1.269753e-01 | 0.896 |
R-HSA-1855204 | Synthesis of IP3 and IP4 in the cytosol | 1.269753e-01 | 0.896 |
R-HSA-69273 | Cyclin A/B1/B2 associated events during G2/M transition | 1.269753e-01 | 0.896 |
R-HSA-5696394 | DNA Damage Recognition in GG-NER | 1.300135e-01 | 0.886 |
R-HSA-114508 | Effects of PIP2 hydrolysis | 1.300135e-01 | 0.886 |
R-HSA-9680350 | Signaling by CSF1 (M-CSF) in myeloid cells | 1.330413e-01 | 0.876 |
R-HSA-5654727 | Negative regulation of FGFR2 signaling | 1.330413e-01 | 0.876 |
R-HSA-187687 | Signalling to ERKs | 1.360588e-01 | 0.866 |
R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 1.420628e-01 | 0.848 |
R-HSA-167200 | Formation of HIV-1 elongation complex containing HIV-1 Tat | 1.480259e-01 | 0.830 |
R-HSA-167246 | Tat-mediated elongation of the HIV-1 transcript | 1.509921e-01 | 0.821 |
R-HSA-167152 | Formation of HIV elongation complex in the absence of HIV Tat | 1.509921e-01 | 0.821 |
R-HSA-167169 | HIV Transcription Elongation | 1.509921e-01 | 0.821 |
R-HSA-451927 | Interleukin-2 family signaling | 1.509921e-01 | 0.821 |
R-HSA-5676590 | NIK-->noncanonical NF-kB signaling | 1.539482e-01 | 0.813 |
R-HSA-5218920 | VEGFR2 mediated vascular permeability | 1.539482e-01 | 0.813 |
R-HSA-5653656 | Vesicle-mediated transport | 1.606144e-01 | 0.794 |
R-HSA-168256 | Immune System | 1.618515e-01 | 0.791 |
R-HSA-1433557 | Signaling by SCF-KIT | 1.627560e-01 | 0.788 |
R-HSA-5654743 | Signaling by FGFR4 | 1.627560e-01 | 0.788 |
R-HSA-168898 | Toll-like Receptor Cascades | 1.657707e-01 | 0.780 |
R-HSA-5607761 | Dectin-1 mediated noncanonical NF-kB signaling | 1.685777e-01 | 0.773 |
R-HSA-69601 | Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | 1.685777e-01 | 0.773 |
R-HSA-69613 | p53-Independent G1/S DNA Damage Checkpoint | 1.685777e-01 | 0.773 |
R-HSA-9824585 | Regulation of MITF-M-dependent genes involved in pigmentation | 1.685777e-01 | 0.773 |
R-HSA-5654741 | Signaling by FGFR3 | 1.685777e-01 | 0.773 |
R-HSA-2514859 | Inactivation, recovery and regulation of the phototransduction cascade | 1.714737e-01 | 0.766 |
R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 1.768851e-01 | 0.752 |
R-HSA-389356 | Co-stimulation by CD28 | 1.772359e-01 | 0.751 |
R-HSA-2514856 | The phototransduction cascade | 1.858055e-01 | 0.731 |
R-HSA-449147 | Signaling by Interleukins | 1.867271e-01 | 0.729 |
R-HSA-112382 | Formation of RNA Pol II elongation complex | 1.886425e-01 | 0.724 |
R-HSA-75955 | RNA Polymerase II Transcription Elongation | 1.914698e-01 | 0.718 |
R-HSA-5250924 | B-WICH complex positively regulates rRNA expression | 1.914698e-01 | 0.718 |
R-HSA-9730414 | MITF-M-regulated melanocyte development | 1.944012e-01 | 0.711 |
R-HSA-5578775 | Ion homeostasis | 1.998937e-01 | 0.699 |
R-HSA-5654736 | Signaling by FGFR1 | 1.998937e-01 | 0.699 |
R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 1.998937e-01 | 0.699 |
R-HSA-2980766 | Nuclear Envelope Breakdown | 2.026825e-01 | 0.693 |
R-HSA-199991 | Membrane Trafficking | 2.030709e-01 | 0.692 |
R-HSA-9845323 | Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 2.109917e-01 | 0.676 |
R-HSA-2428928 | IRS-related events triggered by IGF1R | 2.137424e-01 | 0.670 |
R-HSA-9707616 | Heme signaling | 2.164838e-01 | 0.665 |
R-HSA-1660499 | Synthesis of PIPs at the plasma membrane | 2.164838e-01 | 0.665 |
R-HSA-69615 | G1/S DNA Damage Checkpoints | 2.192158e-01 | 0.659 |
R-HSA-373755 | Semaphorin interactions | 2.192158e-01 | 0.659 |
R-HSA-2428924 | IGF1R signaling cascade | 2.219384e-01 | 0.654 |
R-HSA-74751 | Insulin receptor signalling cascade | 2.219384e-01 | 0.654 |
R-HSA-2404192 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 2.246517e-01 | 0.648 |
R-HSA-8939211 | ESR-mediated signaling | 2.249076e-01 | 0.648 |
R-HSA-71387 | Metabolism of carbohydrates and carbohydrate derivatives | 2.296503e-01 | 0.639 |
R-HSA-6798695 | Neutrophil degranulation | 2.314917e-01 | 0.635 |
R-HSA-167172 | Transcription of the HIV genome | 2.327359e-01 | 0.633 |
R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 2.407374e-01 | 0.618 |
R-HSA-9638482 | Metal ion assimilation from the host | 2.407374e-01 | 0.618 |
R-HSA-9856649 | Transcriptional and post-translational regulation of MITF-M expression and activ... | 2.407374e-01 | 0.618 |
R-HSA-4086398 | Ca2+ pathway | 2.460261e-01 | 0.609 |
R-HSA-674695 | RNA Polymerase II Pre-transcription Events | 2.486568e-01 | 0.604 |
R-HSA-5689603 | UCH proteinases | 2.538914e-01 | 0.595 |
R-HSA-9734767 | Developmental Cell Lineages | 2.583541e-01 | 0.588 |
R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | 2.590900e-01 | 0.587 |
R-HSA-4086400 | PCP/CE pathway | 2.590900e-01 | 0.587 |
R-HSA-5654738 | Signaling by FGFR2 | 2.642532e-01 | 0.578 |
R-HSA-9711123 | Cellular response to chemical stress | 2.648075e-01 | 0.577 |
R-HSA-5668541 | TNFR2 non-canonical NF-kB pathway | 2.719316e-01 | 0.566 |
R-HSA-9707564 | Cytoprotection by HMOX1 | 2.719316e-01 | 0.566 |
R-HSA-5696399 | Global Genome Nucleotide Excision Repair (GG-NER) | 2.744736e-01 | 0.561 |
R-HSA-141444 | Amplification of signal from unattached kinetochores via a MAD2 inhibitory si... | 2.795314e-01 | 0.554 |
R-HSA-141424 | Amplification of signal from the kinetochores | 2.795314e-01 | 0.554 |
R-HSA-1643685 | Disease | 2.819647e-01 | 0.550 |
R-HSA-6807505 | RNA polymerase II transcribes snRNA genes | 2.820473e-01 | 0.550 |
R-HSA-390466 | Chaperonin-mediated protein folding | 2.845546e-01 | 0.546 |
R-HSA-2262752 | Cellular responses to stress | 2.935050e-01 | 0.532 |
R-HSA-8986944 | Transcriptional Regulation by MECP2 | 2.944979e-01 | 0.531 |
R-HSA-74752 | Signaling by Insulin receptor | 2.994186e-01 | 0.524 |
R-HSA-391251 | Protein folding | 2.994186e-01 | 0.524 |
R-HSA-9837999 | Mitochondrial protein degradation | 3.043055e-01 | 0.517 |
R-HSA-2168880 | Scavenging of heme from plasma | 3.091590e-01 | 0.510 |
R-HSA-1280218 | Adaptive Immune System | 3.127986e-01 | 0.505 |
R-HSA-170834 | Signaling by TGF-beta Receptor Complex | 3.139792e-01 | 0.503 |
R-HSA-190236 | Signaling by FGFR | 3.163769e-01 | 0.500 |
R-HSA-3214847 | HATs acetylate histones | 3.187664e-01 | 0.497 |
R-HSA-69618 | Mitotic Spindle Checkpoint | 3.211476e-01 | 0.493 |
R-HSA-9009391 | Extra-nuclear estrogen signaling | 3.235207e-01 | 0.490 |
R-HSA-9842860 | Regulation of endogenous retroelements | 3.258857e-01 | 0.487 |
R-HSA-2559580 | Oxidative Stress Induced Senescence | 3.258857e-01 | 0.487 |
R-HSA-1483255 | PI Metabolism | 3.258857e-01 | 0.487 |
R-HSA-5696398 | Nucleotide Excision Repair | 3.352645e-01 | 0.475 |
R-HSA-2672351 | Stimuli-sensing channels | 3.422144e-01 | 0.466 |
R-HSA-9648025 | EML4 and NUDC in mitotic spindle formation | 3.445151e-01 | 0.463 |
R-HSA-1483249 | Inositol phosphate metabolism | 3.513700e-01 | 0.454 |
R-HSA-1912422 | Pre-NOTCH Expression and Processing | 3.536393e-01 | 0.451 |
R-HSA-2029485 | Role of phospholipids in phagocytosis | 3.626387e-01 | 0.441 |
R-HSA-68875 | Mitotic Prophase | 3.737151e-01 | 0.427 |
R-HSA-2500257 | Resolution of Sister Chromatid Cohesion | 3.759075e-01 | 0.425 |
R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 3.802699e-01 | 0.420 |
R-HSA-162909 | Host Interactions of HIV factors | 3.824398e-01 | 0.417 |
R-HSA-9006931 | Signaling by Nuclear Receptors | 3.858442e-01 | 0.414 |
R-HSA-69481 | G2/M Checkpoints | 3.910452e-01 | 0.408 |
R-HSA-199418 | Negative regulation of the PI3K/AKT network | 3.974218e-01 | 0.401 |
R-HSA-5576891 | Cardiac conduction | 4.016364e-01 | 0.396 |
R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 4.058221e-01 | 0.392 |
R-HSA-913531 | Interferon Signaling | 4.116463e-01 | 0.385 |
R-HSA-9018519 | Estrogen-dependent gene expression | 4.141073e-01 | 0.383 |
R-HSA-3858494 | Beta-catenin independent WNT signaling | 4.141073e-01 | 0.383 |
R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway | 4.161608e-01 | 0.381 |
R-HSA-162599 | Late Phase of HIV Life Cycle | 4.283342e-01 | 0.368 |
R-HSA-2187338 | Visual phototransduction | 4.382881e-01 | 0.358 |
R-HSA-2173782 | Binding and Uptake of Ligands by Scavenger Receptors | 4.441784e-01 | 0.352 |
R-HSA-9856651 | MITF-M-dependent gene expression | 4.441784e-01 | 0.352 |
R-HSA-9755511 | KEAP1-NFE2L2 pathway | 4.461284e-01 | 0.351 |
R-HSA-9612973 | Autophagy | 4.557778e-01 | 0.341 |
R-HSA-162587 | HIV Life Cycle | 4.576877e-01 | 0.339 |
R-HSA-9006936 | Signaling by TGFB family members | 4.633782e-01 | 0.334 |
R-HSA-2467813 | Separation of Sister Chromatids | 4.708744e-01 | 0.327 |
R-HSA-983712 | Ion channel transport | 5.171532e-01 | 0.286 |
R-HSA-9640148 | Infection with Enterobacteria | 5.404011e-01 | 0.267 |
R-HSA-68882 | Mitotic Anaphase | 5.625488e-01 | 0.250 |
R-HSA-2555396 | Mitotic Metaphase and Anaphase | 5.640900e-01 | 0.249 |
R-HSA-8953854 | Metabolism of RNA | 5.776330e-01 | 0.238 |
R-HSA-162906 | HIV Infection | 5.792121e-01 | 0.237 |
R-HSA-3247509 | Chromatin modifying enzymes | 5.894897e-01 | 0.230 |
R-HSA-4839726 | Chromatin organization | 6.106901e-01 | 0.214 |
R-HSA-5688426 | Deubiquitination | 6.188658e-01 | 0.208 |
R-HSA-388841 | Regulation of T cell activation by CD28 family | 6.202119e-01 | 0.207 |
R-HSA-1257604 | PIP3 activates AKT signaling | 6.692208e-01 | 0.174 |
R-HSA-1483257 | Phospholipid metabolism | 6.692208e-01 | 0.174 |
R-HSA-195721 | Signaling by WNT | 6.727223e-01 | 0.172 |
R-HSA-212165 | Epigenetic regulation of gene expression | 7.005202e-01 | 0.155 |
R-HSA-73894 | DNA Repair | 7.374556e-01 | 0.132 |
R-HSA-9824439 | Bacterial Infection Pathways | 7.649261e-01 | 0.116 |
R-HSA-556833 | Metabolism of lipids | 7.819489e-01 | 0.107 |
R-HSA-3700989 | Transcriptional Regulation by TP53 | 8.202430e-01 | 0.086 |
R-HSA-9709957 | Sensory Perception | 8.233384e-01 | 0.084 |
R-HSA-9824446 | Viral Infection Pathways | 9.157765e-01 | 0.038 |
R-HSA-597592 | Post-translational protein modification | 9.405824e-01 | 0.027 |
R-HSA-74160 | Gene expression (Transcription) | 9.755282e-01 | 0.011 |
R-HSA-392499 | Metabolism of proteins | 9.773832e-01 | 0.010 |
R-HSA-212436 | Generic Transcription Pathway | 9.776616e-01 | 0.010 |
R-HSA-73857 | RNA Polymerase II Transcription | 9.859937e-01 | 0.006 |
R-HSA-1430728 | Metabolism | 9.864769e-01 | 0.006 |
Download
kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
---|---|---|---|---|
MST4 |
0.501 | 0.215 | 2 | 0.286 |
RSK3 |
0.491 | 0.066 | -3 | 0.268 |
SGK3 |
0.491 | 0.108 | -3 | 0.281 |
RSK2 |
0.487 | 0.048 | -3 | 0.271 |
PLK4 |
0.487 | 0.116 | 2 | 0.078 |
DCAMKL2 |
0.486 | 0.081 | -3 | 0.324 |
PKN3 |
0.486 | 0.094 | -3 | 0.303 |
MTOR |
0.486 | 0.150 | 1 | 0.511 |
CAMK2B |
0.484 | 0.032 | 2 | 0.137 |
GRK7 |
0.483 | 0.083 | 1 | 0.466 |
TGFBR1 |
0.483 | 0.080 | -2 | 0.730 |
CAMK2G |
0.482 | 0.018 | 2 | 0.127 |
DCAMKL1 |
0.482 | 0.088 | -3 | 0.328 |
PKN2 |
0.482 | 0.069 | -3 | 0.313 |
PKACG |
0.481 | 0.068 | -2 | 0.643 |
TGFBR2 |
0.480 | 0.087 | -2 | 0.746 |
P90RSK |
0.480 | 0.032 | -3 | 0.280 |
CAMK1B |
0.480 | 0.019 | -3 | 0.297 |
TSSK1 |
0.479 | 0.097 | -3 | 0.360 |
P70S6KB |
0.479 | 0.034 | -3 | 0.284 |
CAMK2D |
0.479 | 0.059 | -3 | 0.298 |
RSK4 |
0.478 | 0.031 | -3 | 0.267 |
PLK3 |
0.478 | 0.045 | 2 | 0.098 |
COT |
0.478 | -0.003 | 2 | 0.143 |
GCN2 |
0.478 | 0.038 | 2 | 0.164 |
NDR2 |
0.478 | 0.093 | -3 | 0.316 |
PHKG1 |
0.477 | 0.074 | -3 | 0.320 |
NUAK2 |
0.477 | 0.064 | -3 | 0.318 |
NDR1 |
0.477 | 0.052 | -3 | 0.314 |
PRP4 |
0.477 | 0.266 | -3 | 0.680 |
NIM1 |
0.476 | 0.136 | 3 | 0.548 |
BCKDK |
0.476 | 0.049 | -1 | 0.293 |
WNK1 |
0.476 | 0.040 | -2 | 0.606 |
TBK1 |
0.476 | 0.044 | 1 | 0.507 |
CAMK4 |
0.476 | 0.034 | -3 | 0.302 |
PHKG2 |
0.476 | 0.059 | -3 | 0.316 |
PDHK1 |
0.475 | 0.081 | 1 | 0.469 |
PKCD |
0.475 | 0.036 | 2 | 0.111 |
ALK4 |
0.475 | 0.053 | -2 | 0.726 |
MNK2 |
0.475 | 0.063 | -2 | 0.614 |
AMPKA1 |
0.474 | 0.048 | -3 | 0.337 |
SGK1 |
0.474 | 0.057 | -3 | 0.198 |
ALK2 |
0.474 | 0.055 | -2 | 0.734 |
LATS2 |
0.473 | 0.029 | -5 | 0.520 |
P70S6K |
0.473 | 0.057 | -3 | 0.222 |
ULK2 |
0.473 | 0.001 | 2 | 0.134 |
HUNK |
0.473 | 0.008 | 2 | 0.147 |
PLK1 |
0.473 | 0.025 | -2 | 0.682 |
BMPR2 |
0.473 | -0.010 | -2 | 0.694 |
DSTYK |
0.472 | -0.056 | 2 | 0.156 |
PDHK4 |
0.472 | 0.015 | 1 | 0.463 |
ACVR2A |
0.472 | 0.044 | -2 | 0.734 |
AKT2 |
0.472 | 0.033 | -3 | 0.237 |
PRPK |
0.472 | -0.025 | -1 | 0.300 |
MAPKAPK2 |
0.472 | 0.025 | -3 | 0.262 |
DNAPK |
0.472 | 0.030 | 1 | 0.385 |
AKT1 |
0.471 | 0.048 | -3 | 0.260 |
NLK |
0.471 | 0.017 | 1 | 0.359 |
TTBK2 |
0.471 | -0.051 | 2 | 0.145 |
PKCA |
0.471 | 0.052 | 2 | 0.108 |
AURA |
0.470 | 0.045 | -2 | 0.542 |
PKG2 |
0.470 | 0.045 | -2 | 0.613 |
WNK3 |
0.470 | -0.002 | 1 | 0.442 |
IKKE |
0.470 | -0.004 | 1 | 0.495 |
PKACA |
0.470 | 0.037 | -2 | 0.598 |
CAMK2A |
0.470 | -0.011 | 2 | 0.125 |
NIK |
0.470 | 0.001 | -3 | 0.324 |
PKACB |
0.469 | 0.041 | -2 | 0.609 |
CDC7 |
0.469 | 0.023 | 1 | 0.316 |
NUAK1 |
0.469 | 0.046 | -3 | 0.292 |
NEK7 |
0.469 | -0.011 | -3 | 0.261 |
CLK3 |
0.469 | -0.002 | 1 | 0.284 |
MNK1 |
0.469 | 0.035 | -2 | 0.630 |
ACVR2B |
0.468 | 0.016 | -2 | 0.734 |
GRK6 |
0.468 | -0.053 | 1 | 0.442 |
AKT3 |
0.468 | 0.043 | -3 | 0.210 |
PAK6 |
0.468 | 0.015 | -2 | 0.532 |
MARK4 |
0.468 | 0.062 | 4 | 0.385 |
PLK2 |
0.468 | 0.014 | -3 | 0.267 |
CLK1 |
0.468 | 0.008 | -3 | 0.275 |
NEK2 |
0.467 | 0.012 | 2 | 0.177 |
PRKD1 |
0.467 | 0.024 | -3 | 0.304 |
MAPKAPK3 |
0.467 | -0.013 | -3 | 0.286 |
AMPKA2 |
0.467 | 0.029 | -3 | 0.325 |
PRKX |
0.467 | 0.034 | -3 | 0.284 |
ULK1 |
0.467 | -0.048 | -3 | 0.273 |
TTBK1 |
0.466 | -0.040 | 2 | 0.104 |
LATS1 |
0.466 | -0.006 | -3 | 0.311 |
CAMLCK |
0.466 | -0.012 | -2 | 0.657 |
PRKD2 |
0.466 | 0.011 | -3 | 0.313 |
MOS |
0.466 | -0.034 | 1 | 0.338 |
PIM1 |
0.466 | -0.011 | -3 | 0.281 |
MSK1 |
0.466 | -0.007 | -3 | 0.238 |
SIK |
0.465 | 0.048 | -3 | 0.268 |
NEK9 |
0.465 | -0.005 | 2 | 0.198 |
PKN1 |
0.465 | 0.050 | -3 | 0.246 |
MST3 |
0.465 | 0.089 | 2 | 0.198 |
CDK2 |
0.465 | 0.048 | 1 | 0.298 |
NEK6 |
0.465 | 0.006 | -2 | 0.685 |
AURC |
0.465 | 0.054 | -2 | 0.578 |
CLK2 |
0.465 | 0.017 | -3 | 0.285 |
PKCG |
0.465 | 0.010 | 2 | 0.095 |
PIM3 |
0.465 | -0.032 | -3 | 0.301 |
PKCH |
0.465 | -0.002 | 2 | 0.093 |
BMPR1B |
0.464 | 0.020 | 1 | 0.286 |
MARK2 |
0.464 | 0.053 | 4 | 0.396 |
DAPK2 |
0.464 | -0.022 | -3 | 0.303 |
RAF1 |
0.464 | -0.042 | 1 | 0.438 |
MELK |
0.463 | 0.016 | -3 | 0.317 |
PRKD3 |
0.463 | -0.011 | -3 | 0.254 |
QSK |
0.463 | 0.055 | 4 | 0.367 |
CLK4 |
0.463 | -0.005 | -3 | 0.279 |
BMPR1A |
0.463 | 0.035 | 1 | 0.294 |
AURB |
0.462 | 0.036 | -2 | 0.570 |
CDKL1 |
0.462 | -0.022 | -3 | 0.248 |
SKMLCK |
0.462 | -0.014 | -2 | 0.645 |
PKCT |
0.462 | 0.020 | 2 | 0.105 |
CRIK |
0.462 | 0.078 | -3 | 0.238 |
QIK |
0.462 | 0.037 | -3 | 0.289 |
ATR |
0.462 | -0.052 | 1 | 0.338 |
PDK1 |
0.462 | 0.142 | 1 | 0.577 |
TSSK2 |
0.461 | -0.008 | -5 | 0.541 |
PAK1 |
0.461 | -0.018 | -2 | 0.590 |
ZAK |
0.461 | -0.002 | 1 | 0.526 |
PKR |
0.461 | 0.054 | 1 | 0.336 |
GRK4 |
0.461 | -0.062 | -2 | 0.629 |
PAK3 |
0.461 | -0.020 | -2 | 0.593 |
MEK1 |
0.460 | -0.053 | 2 | 0.152 |
CAMK1G |
0.460 | -0.015 | -3 | 0.252 |
PAK5 |
0.460 | 0.013 | -2 | 0.492 |
MASTL |
0.460 | -0.032 | -2 | 0.569 |
RIPK3 |
0.460 | -0.014 | 3 | 0.540 |
DLK |
0.460 | -0.101 | 1 | 0.473 |
TLK2 |
0.459 | 0.025 | 1 | 0.344 |
WNK4 |
0.459 | 0.024 | -2 | 0.574 |
HRI |
0.459 | -0.011 | -2 | 0.713 |
MSK2 |
0.459 | -0.030 | -3 | 0.219 |
TAO3 |
0.459 | 0.069 | 1 | 0.442 |
GRK1 |
0.459 | -0.051 | -2 | 0.566 |
IKKB |
0.459 | -0.065 | -2 | 0.520 |
PIM2 |
0.459 | 0.007 | -3 | 0.258 |
FAM20C |
0.458 | -0.023 | 2 | 0.066 |
PKCI |
0.458 | 0.021 | 2 | 0.128 |
PKCB |
0.458 | -0.016 | 2 | 0.107 |
RIPK1 |
0.458 | -0.014 | 1 | 0.434 |
MLK1 |
0.458 | -0.074 | 2 | 0.152 |
MARK1 |
0.457 | 0.024 | 4 | 0.371 |
PKCE |
0.457 | 0.014 | 2 | 0.102 |
GRK5 |
0.457 | -0.084 | -3 | 0.266 |
MARK3 |
0.457 | 0.033 | 4 | 0.375 |
MEKK1 |
0.457 | 0.007 | 1 | 0.443 |
CHK1 |
0.457 | -0.015 | -3 | 0.334 |
YSK4 |
0.457 | -0.039 | 1 | 0.467 |
ANKRD3 |
0.457 | -0.072 | 1 | 0.459 |
MAP3K15 |
0.456 | 0.099 | 1 | 0.530 |
EEF2K |
0.456 | 0.049 | 3 | 0.697 |
IKKA |
0.456 | -0.024 | -2 | 0.503 |
SRPK3 |
0.456 | -0.014 | -3 | 0.204 |
ICK |
0.456 | -0.023 | -3 | 0.270 |
ATM |
0.456 | -0.054 | 1 | 0.307 |
MRCKA |
0.456 | 0.021 | -3 | 0.273 |
TAO2 |
0.455 | 0.041 | 2 | 0.152 |
CAMK1D |
0.455 | -0.019 | -3 | 0.249 |
PAK2 |
0.455 | -0.030 | -2 | 0.572 |
CDK3 |
0.455 | 0.041 | 1 | 0.172 |
PAK4 |
0.454 | -0.003 | -2 | 0.502 |
PERK |
0.454 | -0.031 | -2 | 0.706 |
YSK1 |
0.454 | 0.096 | 2 | 0.206 |
CHAK2 |
0.454 | -0.077 | -1 | 0.220 |
SMMLCK |
0.454 | -0.031 | -3 | 0.269 |
SRPK2 |
0.454 | -0.021 | -3 | 0.203 |
PKG1 |
0.453 | 0.024 | -2 | 0.566 |
CDK5 |
0.453 | 0.023 | 1 | 0.211 |
MAPKAPK5 |
0.453 | -0.045 | -3 | 0.211 |
VRK2 |
0.453 | -0.026 | 1 | 0.413 |
DRAK1 |
0.453 | -0.036 | 1 | 0.472 |
NEK11 |
0.453 | 0.024 | 1 | 0.506 |
MYLK4 |
0.452 | -0.037 | -2 | 0.632 |
CDK8 |
0.452 | -0.002 | 1 | 0.251 |
GSK3A |
0.452 | 0.011 | 4 | 0.114 |
CHK2 |
0.452 | -0.015 | -3 | 0.225 |
CAMK1A |
0.452 | -0.004 | -3 | 0.226 |
BRSK2 |
0.452 | -0.017 | -3 | 0.311 |
JNK2 |
0.452 | -0.005 | 1 | 0.219 |
MEKK3 |
0.452 | -0.060 | 1 | 0.437 |
BRSK1 |
0.452 | -0.028 | -3 | 0.295 |
MRCKB |
0.452 | 0.010 | -3 | 0.270 |
SRPK1 |
0.452 | -0.026 | -3 | 0.245 |
IRE1 |
0.451 | -0.038 | 1 | 0.307 |
NEK3 |
0.451 | 0.110 | 1 | 0.463 |
CDK1 |
0.451 | 0.001 | 1 | 0.201 |
IRE2 |
0.451 | -0.048 | 2 | 0.089 |
CDKL5 |
0.451 | -0.036 | -3 | 0.251 |
CDK12 |
0.451 | 0.029 | 1 | 0.218 |
CK2A2 |
0.451 | 0.002 | 1 | 0.236 |
SNRK |
0.451 | -0.066 | 2 | 0.067 |
GSK3B |
0.451 | -0.022 | 4 | 0.105 |
SSTK |
0.450 | -0.013 | 4 | 0.368 |
ERK7 |
0.450 | -0.021 | 2 | 0.069 |
PKCZ |
0.450 | -0.022 | 2 | 0.132 |
TLK1 |
0.449 | -0.068 | -2 | 0.720 |
KIS |
0.449 | 0.010 | 1 | 0.237 |
MEKK2 |
0.449 | -0.017 | 2 | 0.151 |
ERK5 |
0.449 | -0.067 | 1 | 0.268 |
CDK13 |
0.448 | 0.012 | 1 | 0.221 |
HIPK4 |
0.448 | -0.003 | 1 | 0.257 |
TNIK |
0.448 | 0.059 | 3 | 0.661 |
MLK4 |
0.448 | -0.090 | 2 | 0.106 |
MINK |
0.448 | 0.063 | 1 | 0.413 |
HGK |
0.448 | 0.055 | 3 | 0.653 |
CDK19 |
0.447 | -0.000 | 1 | 0.223 |
P38G |
0.447 | -0.002 | 1 | 0.175 |
KHS2 |
0.447 | 0.080 | 1 | 0.392 |
BRAF |
0.447 | -0.083 | -4 | 0.345 |
MEKK6 |
0.447 | 0.034 | 1 | 0.411 |
MEK2 |
0.447 | -0.010 | 2 | 0.170 |
HPK1 |
0.447 | 0.044 | 1 | 0.394 |
MLK2 |
0.447 | -0.086 | 2 | 0.164 |
HIPK1 |
0.447 | 0.006 | 1 | 0.244 |
JNK3 |
0.446 | -0.027 | 1 | 0.255 |
GCK |
0.446 | 0.034 | 1 | 0.389 |
MEK5 |
0.446 | -0.074 | 2 | 0.155 |
LOK |
0.446 | 0.004 | -2 | 0.583 |
P38A |
0.446 | 0.003 | 1 | 0.230 |
KHS1 |
0.445 | 0.069 | 1 | 0.404 |
YANK3 |
0.445 | -0.031 | 2 | 0.041 |
CDK18 |
0.445 | 0.009 | 1 | 0.183 |
CDK9 |
0.445 | 0.007 | 1 | 0.236 |
NEK5 |
0.445 | -0.041 | 1 | 0.390 |
DMPK1 |
0.444 | 0.013 | -3 | 0.286 |
PASK |
0.444 | -0.068 | -3 | 0.286 |
CHAK1 |
0.444 | -0.111 | 2 | 0.158 |
CK1A2 |
0.444 | -0.051 | -3 | 0.097 |
DAPK3 |
0.443 | -0.034 | -3 | 0.297 |
SMG1 |
0.443 | -0.071 | 1 | 0.306 |
IRAK4 |
0.443 | -0.064 | 1 | 0.353 |
CDK17 |
0.443 | -0.009 | 1 | 0.177 |
CDK10 |
0.443 | -0.005 | 1 | 0.199 |
MLK3 |
0.442 | -0.091 | 2 | 0.117 |
DAPK1 |
0.442 | -0.037 | -3 | 0.279 |
NEK1 |
0.442 | 0.041 | 1 | 0.409 |
ROCK2 |
0.442 | 0.002 | -3 | 0.308 |
CDK7 |
0.442 | -0.019 | 1 | 0.219 |
GRK2 |
0.442 | -0.081 | -2 | 0.549 |
TAO1 |
0.441 | 0.050 | 1 | 0.462 |
CDK16 |
0.441 | 0.004 | 1 | 0.183 |
CK1E |
0.441 | -0.058 | -3 | 0.127 |
GAK |
0.441 | -0.033 | 1 | 0.321 |
CK2A1 |
0.441 | -0.013 | 1 | 0.235 |
IRAK1 |
0.441 | -0.106 | -1 | 0.214 |
MPSK1 |
0.441 | 0.023 | 1 | 0.267 |
CDK14 |
0.441 | -0.011 | 1 | 0.222 |
RIPK2 |
0.440 | -0.072 | 1 | 0.517 |
STK33 |
0.439 | -0.065 | 2 | 0.079 |
NEK4 |
0.439 | -0.027 | 1 | 0.383 |
DYRK1A |
0.439 | -0.027 | 1 | 0.279 |
P38B |
0.439 | -0.018 | 1 | 0.211 |
GRK3 |
0.439 | -0.063 | -2 | 0.525 |
MST1 |
0.438 | -0.036 | 1 | 0.412 |
NEK8 |
0.438 | -0.088 | 2 | 0.144 |
DYRK2 |
0.438 | -0.029 | 1 | 0.229 |
ROCK1 |
0.438 | -0.002 | -3 | 0.291 |
HIPK2 |
0.437 | -0.005 | 1 | 0.173 |
ASK1 |
0.437 | 0.025 | 1 | 0.554 |
CK1D |
0.436 | -0.060 | -3 | 0.096 |
DYRK3 |
0.436 | -0.016 | 1 | 0.247 |
SBK |
0.436 | -0.035 | -3 | 0.189 |
CK1G1 |
0.436 | -0.048 | -3 | 0.109 |
MST2 |
0.436 | -0.054 | 1 | 0.400 |
LKB1 |
0.436 | -0.006 | -3 | 0.370 |
HIPK3 |
0.435 | -0.027 | 1 | 0.267 |
ERK2 |
0.435 | -0.054 | 1 | 0.240 |
CDK6 |
0.434 | -0.010 | 1 | 0.210 |
ERK1 |
0.434 | -0.029 | 1 | 0.207 |
LRRK2 |
0.433 | -0.049 | 2 | 0.165 |
HASPIN |
0.433 | -0.025 | -1 | 0.213 |
JNK1 |
0.433 | -0.035 | 1 | 0.234 |
P38D |
0.432 | -0.012 | 1 | 0.155 |
CAMKK1 |
0.431 | -0.132 | -2 | 0.546 |
CAMKK2 |
0.431 | -0.077 | -2 | 0.545 |
TAK1 |
0.431 | -0.112 | 1 | 0.425 |
OSR1 |
0.431 | -0.030 | 2 | 0.190 |
SLK |
0.431 | -0.070 | -2 | 0.524 |
DYRK1B |
0.430 | -0.032 | 1 | 0.197 |
DYRK4 |
0.429 | -0.042 | 1 | 0.196 |
CDK4 |
0.429 | -0.022 | 1 | 0.208 |
MYO3B |
0.429 | 0.037 | 2 | 0.185 |
MYO3A |
0.428 | 0.003 | 1 | 0.362 |
VRK1 |
0.427 | -0.110 | 2 | 0.132 |
PBK |
0.427 | -0.025 | 1 | 0.253 |
PINK1 |
0.426 | -0.155 | 1 | 0.282 |
MAK |
0.426 | -0.008 | -2 | 0.454 |
MOK |
0.423 | -0.019 | 1 | 0.194 |
STLK3 |
0.420 | -0.069 | 1 | 0.458 |
YANK2 |
0.420 | -0.045 | 2 | 0.029 |
BIKE |
0.420 | -0.033 | 1 | 0.241 |
ALPHAK3 |
0.420 | -0.083 | -1 | 0.240 |
TTK |
0.419 | -0.067 | -2 | 0.713 |
BUB1 |
0.417 | -0.040 | -5 | 0.499 |
AAK1 |
0.417 | 0.001 | 1 | 0.163 |
BMPR2_TYR |
0.414 | -0.011 | -1 | 0.344 |
NEK10_TYR |
0.414 | 0.083 | 1 | 0.487 |
PDHK3_TYR |
0.413 | -0.015 | 4 | 0.342 |
JAK1 |
0.413 | 0.066 | 1 | 0.538 |
DDR1 |
0.411 | -0.017 | 4 | 0.334 |
TYK2 |
0.411 | 0.022 | 1 | 0.483 |
PINK1_TYR |
0.411 | -0.042 | 1 | 0.444 |
MAP2K7_TYR |
0.411 | -0.005 | 2 | 0.152 |
PKMYT1_TYR |
0.409 | 0.087 | 3 | 0.606 |
CK1G3 |
0.409 | -0.076 | -3 | 0.045 |
MAP2K4_TYR |
0.409 | 0.003 | -1 | 0.330 |
MST1R |
0.409 | -0.002 | 3 | 0.560 |
EGFR |
0.408 | -0.005 | 1 | 0.585 |
FGFR2 |
0.408 | -0.053 | 3 | 0.580 |
JAK3 |
0.407 | -0.028 | 1 | 0.539 |
FLT3 |
0.406 | -0.033 | 3 | 0.549 |
JAK2 |
0.405 | 0.003 | 1 | 0.502 |
EPHA6 |
0.405 | -0.080 | -1 | 0.240 |
CK1A |
0.405 | -0.080 | -3 | 0.063 |
RET |
0.404 | -0.071 | 1 | 0.483 |
TESK1_TYR |
0.404 | -0.059 | 3 | 0.638 |
LIMK2_TYR |
0.404 | 0.008 | -3 | 0.350 |
MAP2K6_TYR |
0.403 | -0.093 | -1 | 0.324 |
PDHK4_TYR |
0.403 | -0.072 | 2 | 0.153 |
PDGFRA |
0.402 | -0.035 | 3 | 0.556 |
FGFR1 |
0.402 | -0.043 | 3 | 0.533 |
CSF1R |
0.402 | -0.046 | 3 | 0.549 |
TNNI3K_TYR |
0.402 | 0.029 | 1 | 0.395 |
FGFR3 |
0.401 | -0.064 | 3 | 0.571 |
PDGFRB |
0.401 | -0.066 | 3 | 0.557 |
ERBB2 |
0.401 | -0.048 | 1 | 0.564 |
FLT1 |
0.400 | -0.066 | -1 | 0.258 |
FLT4 |
0.400 | -0.064 | 3 | 0.534 |
KDR |
0.400 | -0.054 | 3 | 0.536 |
PDHK1_TYR |
0.400 | -0.116 | -1 | 0.297 |
CK1G2 |
0.399 | -0.069 | -3 | 0.082 |
ROS1 |
0.399 | -0.055 | 3 | 0.520 |
KIT |
0.398 | -0.071 | 3 | 0.555 |
LIMK1_TYR |
0.398 | -0.058 | 2 | 0.156 |
MUSK |
0.396 | -0.019 | 1 | 0.543 |
NTRK2 |
0.395 | -0.078 | 3 | 0.521 |
INSRR |
0.395 | -0.110 | 3 | 0.538 |
FGFR4 |
0.394 | -0.059 | -1 | 0.197 |
NTRK1 |
0.393 | -0.101 | -1 | 0.229 |
TNK1 |
0.393 | -0.041 | 3 | 0.519 |
MET |
0.392 | -0.072 | 3 | 0.527 |
EPHA4 |
0.392 | -0.112 | 2 | 0.094 |
YES1 |
0.392 | -0.092 | -1 | 0.233 |
WEE1_TYR |
0.392 | -0.061 | -1 | 0.220 |
TYRO3 |
0.391 | -0.134 | 3 | 0.549 |
HCK |
0.391 | -0.097 | -1 | 0.250 |
TEK |
0.391 | -0.114 | 3 | 0.508 |
AXL |
0.389 | -0.110 | 3 | 0.523 |
PTK2 |
0.389 | -0.061 | -1 | 0.277 |
ERBB4 |
0.389 | -0.031 | 1 | 0.507 |
DDR2 |
0.389 | -0.060 | 3 | 0.547 |
MERTK |
0.389 | -0.111 | 3 | 0.514 |
NTRK3 |
0.388 | -0.081 | -1 | 0.201 |
LCK |
0.388 | -0.084 | -1 | 0.252 |
FRK |
0.387 | -0.089 | -1 | 0.237 |
FER |
0.387 | -0.149 | 1 | 0.377 |
INSR |
0.387 | -0.101 | 3 | 0.509 |
BTK |
0.387 | -0.140 | -1 | 0.209 |
EPHB4 |
0.386 | -0.165 | -1 | 0.218 |
ITK |
0.386 | -0.104 | -1 | 0.243 |
FYN |
0.386 | -0.084 | -1 | 0.260 |
EPHA3 |
0.386 | -0.119 | 2 | 0.083 |
SRMS |
0.386 | -0.147 | 1 | 0.384 |
SYK |
0.385 | -0.066 | -1 | 0.249 |
ABL2 |
0.385 | -0.106 | -1 | 0.218 |
FGR |
0.385 | -0.121 | 1 | 0.364 |
TEC |
0.385 | -0.124 | -1 | 0.185 |
ALK |
0.384 | -0.114 | 3 | 0.496 |
BLK |
0.383 | -0.098 | -1 | 0.252 |
EPHB1 |
0.383 | -0.167 | 1 | 0.401 |
TNK2 |
0.383 | -0.116 | 3 | 0.523 |
IGF1R |
0.382 | -0.087 | 3 | 0.460 |
PTK6 |
0.382 | -0.137 | -1 | 0.183 |
EPHB2 |
0.382 | -0.152 | -1 | 0.206 |
TXK |
0.382 | -0.120 | 1 | 0.330 |
EPHA7 |
0.382 | -0.126 | 2 | 0.083 |
EPHA1 |
0.382 | -0.127 | 3 | 0.508 |
ABL1 |
0.381 | -0.116 | -1 | 0.214 |
PTK2B |
0.381 | -0.098 | -1 | 0.183 |
LTK |
0.381 | -0.128 | 3 | 0.511 |
SRC |
0.380 | -0.090 | -1 | 0.237 |
EPHA8 |
0.380 | -0.107 | -1 | 0.218 |
BMX |
0.380 | -0.119 | -1 | 0.200 |
EPHB3 |
0.379 | -0.164 | -1 | 0.201 |
CSK |
0.378 | -0.117 | 2 | 0.098 |
LYN |
0.377 | -0.114 | 3 | 0.487 |
EPHA5 |
0.377 | -0.144 | 2 | 0.066 |
ZAP70 |
0.377 | -0.034 | -1 | 0.242 |
EPHA2 |
0.376 | -0.114 | -1 | 0.206 |
MATK |
0.374 | -0.121 | -1 | 0.180 |
FES |
0.370 | -0.097 | -1 | 0.177 |